1
|
Puillandre N, Miralles A, Brouillet S, Fedosov A, Fischell F, Patmanidis S, Vences M. Species Delimitation and Exploration of Species Partitions with ASAP and LIMES. Methods Mol Biol 2024; 2744:313-334. [PMID: 38683328 DOI: 10.1007/978-1-0716-3581-0_20] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/01/2024]
Abstract
DNA barcoding plays an important role in exploring undescribed biodiversity and is increasingly used to delimit lineages at the species level (see Chap. 4 by Miralles et al.). Although several approaches and programs have been developed to perform species delimitation from datasets of single-locus DNA sequences, such as DNA barcodes, most of these were not initially provided as user-friendly GUI-driven executables. In spite of their differences, most of these tools share the same goal, i.e., inferring de novo a partition of subsets, potentially each representing a distinct species. More recently, a proposed common exchange format for the resulting species partitions (SPART) has been implemented by several of these tools, paving the way toward developing an interoperable digital environment entirely dedicated to integrative and comparative species delimitation. In this chapter, we provide detailed protocols for the use of two bioinformatic tools, one for single locus molecular species delimitation (ASAP) and one for statistical comparison of species partitions resulting from any kind of species delimitation analyses (LIMES).
Collapse
Affiliation(s)
- Nicolas Puillandre
- Institut de Systématique, Évolution, Biodiversité (ISYEB), Muséum National d'Histoire Naturelle, CNRS, Sorbonne Université, EPHE, Paris, France
| | - Aurélien Miralles
- Institut de Systématique, Évolution, Biodiversité (ISYEB), Muséum National d'Histoire Naturelle, CNRS, Sorbonne Université, EPHE, Paris, France
- Department of Evolutionary Biology, Zoological Institute, Technische Universität Braunschweig, Braunschweig, Germany
| | - Sophie Brouillet
- Institut de Systématique, Évolution, Biodiversité (ISYEB), Muséum National d'Histoire Naturelle, CNRS, Sorbonne Université, EPHE, Paris, France
| | - Alexander Fedosov
- Department of Zoology, Swedish Museum of Natural History, Stockholm, Sweden
| | - Frank Fischell
- Institute of Zoology, University of Cologne, Köln, Germany
| | - Stefanos Patmanidis
- School of Electrical and Computer Engineering, National Technical University of Athens, Athens, Greece
| | - Miguel Vences
- Department of Evolutionary Biology, Zoological Institute, Technische Universität Braunschweig, Braunschweig, Germany.
| |
Collapse
|
2
|
David MS, Vintejoux E, Kucharczak F, Brouillet S, Rougier N, Huberlant S. Impact of Caesarean section on pregnancy outcomes in ART after transfer of one or more frozen blastocysts. J Gynecol Obstet Hum Reprod 2024; 53:102692. [PMID: 37979690 DOI: 10.1016/j.jogoh.2023.102692] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2023] [Revised: 10/03/2023] [Accepted: 11/15/2023] [Indexed: 11/20/2023]
Abstract
INTRODUCTION The prevalence of Caesarean delivery is rising steadily worldwide, and it is important to identify its future impact on fertility. A number of articles have been published on this subject, but the impact of Caesarean section on reproductive outcomes is still under debate, and none of these articles focus exclusively on frozen blastocysts. OBJECTIVE The aim of this study was to evaluate the impact of a previous Caesarean delivery compared with a previous vaginal delivery on the chances of a live birth following the transfer of one or more frozen embryos at the blastocyst stage. METHODS This was a retrospective, bicentric study at the University Hospitals of Nîmes and Montpellier, conducted between January 1st, 2016 and February 1st, 2021. Three hundred and ninety women with a history of childbirth and a transfer of one or more frozen embryos at blastocyst stage were included in the analysis. The primary outcome was the number of live births. Secondary outcomes were: the rate of positive HCG, miscarriage, ectopic pregnancy and clinical pregnancy, as well as the live birth rate according to the presence or absence of an isthmocele. RESULTS Of the 390 patients included, 118 had a previous Caesarean delivery and 272 a vaginal delivery. No statistically significant differences were found for the primary (p = 0.9) or secondary outcomes. A trend towards lower live birth rates was observed in patients with isthmoceles, but this did not reach significance (p>0.9). On the other hand, transfers were more often described as difficult in the Caesarean delivery group (p = 0.011). CONCLUSION Our study found no effect of previous Caesarean delivery on the chances of live birth after transferring one or more frozen blastocysts. However, further prospective studies are needed to confirm these results.
Collapse
Affiliation(s)
- Marie-Sophie David
- Department of reproductive medicine, Obstetrics and Gynecology, CHU Arnaud de Villeneuve, 371 avenue du Doyen Gaston Giraud, Montpellier, France; Department of Obstetrics and Gynecology, CHU Nîmes, University of Montpellier, Nîmes, France
| | - Emmanuelle Vintejoux
- Department of reproductive medicine, Obstetrics and Gynecology, CHU Arnaud de Villeneuve, 371 avenue du Doyen Gaston Giraud, Montpellier, France
| | - Florentin Kucharczak
- Department of Biostatistics, Epidemiology, Public Health and Innovation in Methodology (BESPIM), CHU Nîmes, University of Montpellier, Nîmes, France
| | - Sophie Brouillet
- Laboratory of Medically Assisted Reproduction, CHU Arnaud de Villeneuve, 371 avenue du Doyen Gaston Giraud, Montpellier, France
| | - Nathalie Rougier
- Laboratory of Medically Assisted Reproduction, CHU Nîmes, University of Montpellier, Nîmes, France
| | - Stéphanie Huberlant
- Department of Obstetrics and Gynecology, CHU Nîmes, University of Montpellier, Nîmes, France; University of Nîmes-Montpellier, France.
| |
Collapse
|
3
|
Brouillet S, Ranisavljevic N, Sonigo C, Haquet E, Bringer-Deutsch S, Loup-Cabaniols V, Hamamah S, Willems M, Anahory T. Should we perform oocyte accumulation to preserve fertility in women with Turner syndrome? A multicenter study and systematic review of the literature. Hum Reprod 2023; 38:1733-1745. [PMID: 37381072 DOI: 10.1093/humrep/dead135] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2023] [Revised: 06/05/2023] [Indexed: 06/30/2023] Open
Abstract
STUDY QUESTION Should we perform oocyte accumulation to preserve fertility in women with Turner syndrome (TS)? SUMMARY ANSWER The oocyte cryopreservation strategy is not well adapted for all TS women as their combination of high basal FSH with low basal AMH and low percentage of 46,XX cells in the karyotype significantly reduces the chances of freezing sufficient mature oocytes for fertility preservation. WHAT IS KNOWN ALREADY An oocyte cryopreservation strategy requiring numerous stimulation cycles is needed to preserve fertility in TS women, to compensate for the low ovarian response, the possible oocyte genetic alterations, the reduced endometrial receptivity, and the increased rate of miscarriage, observed in this specific population. The validation of reliable predictive biomarkers of ovarian response to hormonal stimulation in TS patients is necessary to help practitioners and patients choose the best-personalized fertility preservation strategy. STUDY DESIGN, SIZE, DURATION A retrospective bicentric study was performed from 1 January 2011 to 1 January 2023. Clinical and biological data from all TS women who have received from ovarian stimulation for fertility preservation were collected. A systematic review of the current literature on oocyte retrieval outcomes after ovarian stimulation in TS women was also performed (PROSPERO registration number: CRD42022362352). PARTICIPANTS/MATERIALS, SETTING, METHODS A total of 14 TS women who had undergone ovarian stimulation for fertility preservation were included, representing the largest cohort of TS patients published to date (n = 14 patients, 24 cycles). The systematic review of the literature identified 34 additional TS patients with 47 oocyte retrieval outcomes after ovarian stimulation in 14 publications (n = 48 patients, n = 71 cycles in total). MAIN RESULTS AND THE ROLE OF CHANCE The number of cryopreserved mature oocytes on the first cycle for TS patients was low (4.0 ± 3.7). Oocyte accumulation was systematically proposed to increase fertility potential and was accepted by 50% (7/14) of patients (2.4 ± 0.5 cycles), leading to an improved total number of 10.9 ± 7.2 cryopreserved mature oocytes per patient. In the group who refused the oocyte accumulation strategy, only one patient exceeded the threshold of 10 mature cryopreserved oocytes. In contrast, 57.1% (4/7) and 42.9% (3/7) of patients who have underwent the oocyte accumulation strategy reached the threshold of 10 and 15 mature cryopreserved oocytes, respectively (OR = 8 (0.6; 107.0), P = 0.12; OR= 11 (0.5; 282.1), P = 0.13). By analyzing all the data published to date and combining it with our data (n = 48 patients, n = 71 cycles), low basal FSH and high AMH concentrations as well as a higher percentage of 46,XX cells in the karyotype were significantly associated with a higher number of cryopreserved oocytes after the first cycle. Moreover, the combination of low basal FSH concentration (<5.9 IU/l), high AMH concentration (>1.13 ng/ml), and the presence of 46,XX cells (>1%) was significantly predictive of obtaining at least six cryopreserved oocytes in the first cycle, representing objective criteria for identifying patients with real chances of preserving an adequate fertility potential by oocyte cryopreservation. LIMITATIONS, REASONS FOR CAUTION Our results should be analyzed with caution, as the optimal oocyte number needed for successful live birth in TS patients is still unknown due to the low number of reports their oocyte use in the literature to date. WIDER IMPLICATIONS OF THE FINDINGS TS patients should benefit from relevant clinical evaluation, genetic counseling and psychological support to make an informed choice regarding their fertility preservation technique, as numerous stimulation cycles would be necessary to preserve a high number of oocytes. STUDY FUNDING/COMPETING INTEREST(S) This research received no external funding. The authors declare no conflict of interest. TRIAL REGISTRATION NUMBER N/A.
Collapse
Affiliation(s)
- S Brouillet
- Department of Reproductive Biology-CECOS, CHU and University of Montpellier, Montpellier, France
- Univ Montpellier, DEFE, INSERM 1203, Embryo Development Fertility Environment, Montpellier, France
| | - N Ranisavljevic
- Department of Reproductive Medicine, CHU and University of Montpellier, Montpellier, France
| | - C Sonigo
- Department of Reproductive Medicine and Fertility Preservation, Université Paris Saclay, Assistance Publique Hôpitaux de Paris, Antoine Beclere Hospital, Clamart, France
- Université Paris Saclay, INSERM, Physiologie et Physiopathologie Endocrinienne, Le Kremlin-Bicêtre, France
| | - E Haquet
- Department of Medical Genetics, CHU and University of Montpellier, Montpellier, France
| | - S Bringer-Deutsch
- Department of Reproductive Medicine, CHU and University of Montpellier, Montpellier, France
| | - V Loup-Cabaniols
- Department of Reproductive Biology-CECOS, CHU and University of Montpellier, Montpellier, France
| | - S Hamamah
- Department of Reproductive Biology-CECOS, CHU and University of Montpellier, Montpellier, France
- Univ Montpellier, DEFE, INSERM 1203, Embryo Development Fertility Environment, Montpellier, France
| | - M Willems
- Department of Medical Genetics, CHU and University of Montpellier, Montpellier, France
- Institute for Neurosciences of Montpellier, U1298, Univ Montpellier, INSERM, Montpellier, France
| | - T Anahory
- Department of Reproductive Medicine, CHU and University of Montpellier, Montpellier, France
| |
Collapse
|
4
|
Duport Percier M, Brouillet S, Mollevi C, Duraes M, Anahory T, Ranisavljevic N. Serum progesterone concentration on pregnancy test day might predict ongoing pregnancy after controlled ovarian stimulation and fresh embryo transfer. Front Endocrinol (Lausanne) 2023; 14:1191648. [PMID: 37455896 PMCID: PMC10338216 DOI: 10.3389/fendo.2023.1191648] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/22/2023] [Accepted: 06/01/2023] [Indexed: 07/18/2023] Open
Abstract
Progesterone (P4) is essential for pregnancy. A controlled ovarian stimulation (COS) leads to a iatrogenic luteal defect that indicates a luteal phase support (LPS) at least until pregnancy test day. Some clinicians continue the LPS until week 8 or later, when P4 is mainly secreted by syncytiotrophoblast cells.Measuring serum P4 on pregnancy test day after a fresh embryo transfer could help to identify women who might benefit from prolonged LPS. In women with LPS based on P4 administered by the rectal route, P4 concentration on pregnancy test day was significantly higher in patients with ongoing pregnancy than in patients with abnormal pregnancy.This monocentric retrospective study used data on 99 consecutive cycles of COS, triggered with human chorionic gonadotropin, followed by fresh embryo transfer resulting in a positive pregnancy test (>100 IU/L) (from November 2020 to November 2022). Patients undergoing preimplantation genetic screening or with ectopic pregnancy were excluded. All patients received standard luteal phase support (i.e. micronized vaginal progesterone 600 mg per day for 15 days). The primary endpoint was P4 concentration at day 15 after oocyte retrieval (pregnancy test day) in women with ongoing pregnancy for >12 weeks and in patients with miscarriage before week 12 of pregnancy.The median P4 concentration [range] at pregnancy test day was higher in women with ongoing pregnancy than in women with miscarriage (55.9 ng/mL [11.6; 290.6] versus 18.1 ng/mL [8.3; 140.9], p = 0.002). A P4 concentration ≥16.5 ng/mL at pregnancy test day was associated with higher ongoing pregnancy rate (OR = 12.5, 95% CI 3.61 - 43.33, p <0.001). A P4 concentration ≥16.5 ng/mL at pregnancy test day was significantly associated with higher live birth rate (OR = 11.88, 95% CI 3.30-42.71, p <0.001).After COS and fresh embryo transfer, the risk of miscarriage is higher in women who discontinue luteal support after 15 days, as recommended, but with P4 concentration <16.5 ng/mL. The benefit of individualized prolonged luteal phase support should be evaluated.
Collapse
Affiliation(s)
- Marie Duport Percier
- Department of Reproductive Medicine, Montpellier University Hospital, University of Montpellier, Montpellier, France
| | - Sophie Brouillet
- Department of Reproductive Biology-CECOS, Montpellier University Hospital, University of Montpellier, Montpellier, France
- Embryo Development Fertility Environment, University of Montpellier, INSERM 1203, Montpellier, France
| | - Caroline Mollevi
- Institute of Epidemiology and Public Health, Montpellier University Hospital, University of Montpellier, INSERM, Montpellier, France
| | - Martha Duraes
- Department of Reproductive Medicine, Montpellier University Hospital, University of Montpellier, Montpellier, France
| | - Tal Anahory
- Department of Reproductive Medicine, Montpellier University Hospital, University of Montpellier, Montpellier, France
| | - Noemie Ranisavljevic
- Department of Reproductive Medicine, Montpellier University Hospital, University of Montpellier, Montpellier, France
| |
Collapse
|
5
|
Coudert A, Cazin C, Amiri-Yekta A, Ben Mustapha SF, Zouari R, Bessonat J, Zoghmar A, Clergeau A, Metzler-Guillemain C, Triki C, Lejeune H, Sermondade N, Pipiras E, Prisant N, Cedrin I, Koscinski I, Keskes L, Lestrade F, Hesters L, Rives N, Dorphin B, Guichet A, Patrat C, Dulioust E, Feraille A, Robert F, Brouillet S, Morel F, Perrin A, Rougier N, Bieth E, Sorlin A, Siffroi JP, Ben Khelifa M, Boiterelle F, Hennebicq S, Satre V, Arnoult C, Coutton C, Barbotin AL, Thierry-Mieg N, Kherraf ZE, Ray PF. Genetic causes of macrozoospermia and proposal for an optimized genetic diagnosis strategy based on sperm parameters. J Genet Genomics 2023:S1673-8527(23)00094-2. [PMID: 37116580 DOI: 10.1016/j.jgg.2023.04.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2023] [Revised: 04/14/2023] [Accepted: 04/16/2023] [Indexed: 04/30/2023]
Affiliation(s)
- Alicia Coudert
- Genetic Epigenetic and Therapies of Infertility team, Institute for Advanced Biosciences, Inserm U 1209, CNRS UMR 5309, Université Grenoble Alpes, 38000 Grenoble, France; CHU Grenoble Alpes, UM GI-DPI, Grenoble, 38000, France; CHU Grenoble Alpes, UM de Génétique Chromosomique, 38000 Grenoble, France
| | - Caroline Cazin
- Genetic Epigenetic and Therapies of Infertility team, Institute for Advanced Biosciences, Inserm U 1209, CNRS UMR 5309, Université Grenoble Alpes, 38000 Grenoble, France; CHU Grenoble Alpes, UM GI-DPI, Grenoble, 38000, France
| | - Amir Amiri-Yekta
- Genetic Epigenetic and Therapies of Infertility team, Institute for Advanced Biosciences, Inserm U 1209, CNRS UMR 5309, Université Grenoble Alpes, 38000 Grenoble, France; CHU Grenoble Alpes, UM GI-DPI, Grenoble, 38000, France; Department of Genetics, Reproductive Biomedicine Research Center, Royan Institute for Reproductive Biomedicine, ACECR, Tehran, Iran
| | | | - Raoudha Zouari
- Polyclinique les Jasmins, Centre d'Aide Médicale à la Procréation, Centre Urbain Nord, 1003 Tunis, Tunisia
| | - Julien Bessonat
- CHU Grenobles Alpes, UF de Biologie de la Procréation, 38000 Grenoble, France
| | - Abdelali Zoghmar
- Reproduction Sciences and Surgery Clinique, Ibn Rochd, Constantine, Algeria
| | - Antoine Clergeau
- CHU Caen, CECOS de Caen, Département de Biologie, Unité de Biologie de la Reproduction, 14033 Caen, France
| | - Catherine Metzler-Guillemain
- Assistance-Publique des Hôpitaux de Marseille (AP-HM), Pôle Femmes-Parents-Enfants, Centre Clinico-biologique AMP-CECOS, Marseille, France and Aix Marseille Univ, INSERM, MMG, UMR 1251, Marseille, France
| | - Chema Triki
- Clinique Hannibal, Centre d'AMP, les berges du lac, 1053 Tunis, Tunisia
| | - Hervé Lejeune
- Reproductive Medicine Department, Hospices Civil de Lyon, Lyon, France
| | | | - Eva Pipiras
- Hôpital Jean Verdier, Université Sorbonne Paris Nord, Paris, France
| | | | - Isabelle Cedrin
- Service de Médecine de la Reproduction, CHU Jean Verdier, Paris, France
| | | | | | - Florence Lestrade
- CHR Metz-Thionville, Service d'Assistance Médicale à la Procréation, 57530 Ars-Laquenexy, France
| | - Laetitia Hesters
- Laboratoire de Fécondation in vitro, Hôpital Antoine Béclère, France
| | - Nathalie Rives
- Univ Rouen Normandie, Inserm U1239, NorDIC, Adrenal and Gonadal Pathophysiology, Reproductive Biology Laboratory-CECOS, Rouen University Hospital, 76031 Rouen cedex, France
| | - Béatrice Dorphin
- CHAL Centre Hospitalier Alpes Léman, Centre AMP74, 74130 Contamine-sur-Arve
| | - Agnes Guichet
- CHU Angers, Service de Génétique, 49933 Angers, INSERM U1083 France
| | - Catherine Patrat
- Service de Biologie de la Reproduction - CECOS Hopital Cochin, 74014, Paris
| | - Emmanuel Dulioust
- Service de Biologie de la Reproduction - CECOS Hopital Cochin, 74014, Paris
| | - Aurélie Feraille
- Univ Rouen Normandie, Inserm U1239, NorDIC, Adrenal and Gonadal Pathophysiology, Reproductive Biology Laboratory-CECOS, Rouen University Hospital, 76031 Rouen cedex, France
| | - François Robert
- IRH Médicentre, Clinique du Val d'Ouest, 39 chemin de la Vernique, 69 130 Ecully, France
| | - Sophie Brouillet
- CHU Arnaud De Villeneuve, Biologie de la Reproduction, 34000 Montpellier, France
| | - Frédéric Morel
- Faculté de médecine et des sciences de la santé, Université de Brest, EFS, UMR1078, GGB, Brest, France; Service de Génétique Médicale et Biologie de la Reproduction, CHU de Brest, Brest, France
| | - Aurore Perrin
- Faculté de médecine et des sciences de la santé, Université de Brest, EFS, UMR1078, GGB, Brest, France; Service de Génétique Médicale et Biologie de la Reproduction, CHU de Brest, Brest, France
| | - Nathalie Rougier
- CHRU Nîmes, Laboratoire d'Assistance Médicale à la Procréation, 30029 Nîmes, France
| | - Eric Bieth
- CHU Toulouse, Service de Génétique, 31059 Toulouse, France
| | - Arthur Sorlin
- Laboratoire national de santé, 1 Rue Louis Rech, L-3555 Dudelange, Luxembourg
| | - Jean-Pierre Siffroi
- Sorbonne Université, INSERM, UMRS_933, AP-HP, Hôpital Armand Trousseau, F-75012 Paris, France
| | | | - Florence Boiterelle
- Service d'assistance médicale à la procréation-Biologie de la reproduction, hôpital de Poissy, 78300 Poissy, France; EA 7404-GIG, UFR des sciences de la santé Simone-Veil, université de Versailles-Saint-Quentin-en-Yvelines, Paris Saclay, 78180 Montigny-le-Bretonneux, France
| | - Sylvianne Hennebicq
- Genetic Epigenetic and Therapies of Infertility team, Institute for Advanced Biosciences, Inserm U 1209, CNRS UMR 5309, Université Grenoble Alpes, 38000 Grenoble, France; CHU Grenobles Alpes, UF de Biologie de la Procréation, 38000 Grenoble, France
| | - Veronique Satre
- Genetic Epigenetic and Therapies of Infertility team, Institute for Advanced Biosciences, Inserm U 1209, CNRS UMR 5309, Université Grenoble Alpes, 38000 Grenoble, France; CHU Grenoble Alpes, UM de Génétique Chromosomique, 38000 Grenoble, France
| | - Christophe Arnoult
- Genetic Epigenetic and Therapies of Infertility team, Institute for Advanced Biosciences, Inserm U 1209, CNRS UMR 5309, Université Grenoble Alpes, 38000 Grenoble, France
| | - Charles Coutton
- Genetic Epigenetic and Therapies of Infertility team, Institute for Advanced Biosciences, Inserm U 1209, CNRS UMR 5309, Université Grenoble Alpes, 38000 Grenoble, France; CHU Grenoble Alpes, UM de Génétique Chromosomique, 38000 Grenoble, France
| | - Anne-Laure Barbotin
- CHU Lille, Hôpital Jeanne De Flandre, Laboratoire de Biologie de la Reproduction-Spermiologie, 59037 Lille, France
| | | | - Zine-Eddine Kherraf
- Genetic Epigenetic and Therapies of Infertility team, Institute for Advanced Biosciences, Inserm U 1209, CNRS UMR 5309, Université Grenoble Alpes, 38000 Grenoble, France; CHU Grenoble Alpes, UM GI-DPI, Grenoble, 38000, France
| | - Pierre F Ray
- Genetic Epigenetic and Therapies of Infertility team, Institute for Advanced Biosciences, Inserm U 1209, CNRS UMR 5309, Université Grenoble Alpes, 38000 Grenoble, France; CHU Grenoble Alpes, UM GI-DPI, Grenoble, 38000, France.
| |
Collapse
|
6
|
Del Llano E, Perrin A, Morel F, Devillard F, Harbuz R, Satre V, Amblard F, Bidart M, Hennebicq S, Brouillet S, Ray PF, Coutton C, Martinez G. Sperm Meiotic Segregation Analysis of Reciprocal Translocations Carriers: We Have Bigger FISH to Fry. Int J Mol Sci 2023; 24:ijms24043664. [PMID: 36835074 PMCID: PMC9965694 DOI: 10.3390/ijms24043664] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2022] [Revised: 02/06/2023] [Accepted: 02/09/2023] [Indexed: 02/16/2023] Open
Abstract
Reciprocal translocation (RT) carriers produce a proportion of unbalanced gametes that expose them to a higher risk of infertility, recurrent miscarriage, and fetus or children with congenital anomalies and developmental delay. To reduce these risks, RT carriers can benefit from prenatal diagnosis (PND) or preimplantation genetic diagnosis (PGD). Sperm fluorescence in situ hybridization (spermFISH) has been used for decades to investigate the sperm meiotic segregation of RT carriers, but a recent report indicates a very low correlation between spermFISH and PGD outcomes, raising the question of the usefulness of spermFISH for these patients. To address this point, we report here the meiotic segregation of 41 RT carriers, the largest cohort reported to date, and conduct a review of the literature to investigate global segregation rates and look for factors that may or may not influence them. We confirm that the involvement of acrocentric chromosomes in the translocation leads to more unbalanced gamete proportions, in contrast to sperm parameters or patient age. In view of the dispersion of balanced sperm rates, we conclude that routine implementation of spermFISH is not beneficial for RT carriers.
Collapse
Affiliation(s)
- Edgar Del Llano
- Genetic Epigenetic and Therapies of Infertility, Institute for Advanced Biosciences INSERM U1209, CNRS UMR5309, 38000 Grenoble, France
| | - Aurore Perrin
- Department of Medical Genetics and Reproductive Biology, Brest University Regional Hospital, 29200 Brest, France
- Inserm, Université de Bretagne Occidentale, EFS, UMR 1078, GGB, 29200 Brest, France
| | - Frédéric Morel
- Department of Medical Genetics and Reproductive Biology, Brest University Regional Hospital, 29200 Brest, France
- Inserm, Université de Bretagne Occidentale, EFS, UMR 1078, GGB, 29200 Brest, France
| | - Françoise Devillard
- UM de Génétique Chromosomique, Hôpital Couple-Enfant, Centre Hospitalier Universitaire de Grenoble, 38000 Grenoble, France
| | - Radu Harbuz
- UM de Génétique Chromosomique, Hôpital Couple-Enfant, Centre Hospitalier Universitaire de Grenoble, 38000 Grenoble, France
| | - Véronique Satre
- Genetic Epigenetic and Therapies of Infertility, Institute for Advanced Biosciences INSERM U1209, CNRS UMR5309, 38000 Grenoble, France
- UM de Génétique Chromosomique, Hôpital Couple-Enfant, Centre Hospitalier Universitaire de Grenoble, 38000 Grenoble, France
| | - Florence Amblard
- UM de Génétique Chromosomique, Hôpital Couple-Enfant, Centre Hospitalier Universitaire de Grenoble, 38000 Grenoble, France
| | - Marie Bidart
- Genetic Epigenetic and Therapies of Infertility, Institute for Advanced Biosciences INSERM U1209, CNRS UMR5309, 38000 Grenoble, France
| | - Sylviane Hennebicq
- Genetic Epigenetic and Therapies of Infertility, Institute for Advanced Biosciences INSERM U1209, CNRS UMR5309, 38000 Grenoble, France
- Centre Clinique et Biologique d’Assistance Médicale à la Procréation, Hôpital Couple-Enfant, Centre Hospitalier Universitaire de Grenoble, 38000 Grenoble, France
| | - Sophie Brouillet
- DEFE, Université de Montpellier, INSERM 1203, Hôpital Arnaud de Villeneuve, CHU de Montpellier, IRMB, 80 Avenue Augustin Fliche, CEDEX 05, 34295 Montpellier, France
| | - Pierre F. Ray
- Genetic Epigenetic and Therapies of Infertility, Institute for Advanced Biosciences INSERM U1209, CNRS UMR5309, 38000 Grenoble, France
| | - Charles Coutton
- Genetic Epigenetic and Therapies of Infertility, Institute for Advanced Biosciences INSERM U1209, CNRS UMR5309, 38000 Grenoble, France
- UM de Génétique Chromosomique, Hôpital Couple-Enfant, Centre Hospitalier Universitaire de Grenoble, 38000 Grenoble, France
| | - Guillaume Martinez
- Genetic Epigenetic and Therapies of Infertility, Institute for Advanced Biosciences INSERM U1209, CNRS UMR5309, 38000 Grenoble, France
- UM de Génétique Chromosomique, Hôpital Couple-Enfant, Centre Hospitalier Universitaire de Grenoble, 38000 Grenoble, France
- Correspondence:
| |
Collapse
|
7
|
Mesnil M, Ranisavljevic N, Brouillet S, Ducrocq B, Reignier A, Yazbeck C, Metzler-Guillemain C, Ohl J, Brunet L, Letur H, Ravel C. [EUGIC (Extension of the Use of Gametes in Intra-Conjugal): New uses of gametes within the couple]. Gynecol Obstet Fertil Senol 2023; 51:200-205. [PMID: 36681149 DOI: 10.1016/j.gofs.2023.01.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/20/2022] [Revised: 01/11/2023] [Accepted: 01/15/2023] [Indexed: 01/19/2023]
Abstract
OBJECTIVE New possibilities for using gametes within a couple were created by the French law of August 2, 2021 related to bioethics by opening Assisted Reproductive Technics (ART) to all women. It concerns previously self-preserved gametes, thus avoiding the need for gamete donation. The objective of our study is to evaluate the perception of these new uses by ART practitioners. METHOD A questionnaire of twelve short questions was sent to professionals concerned with gamete donation. RESULTS One hundred and ten professionals answered the questionnaire. The majority of them approve of the Reception of Oocytes from the Partner (ROPA), notably if there is a medical indication. Requests are rarer for the care of trans* people, and raise more questions. Although less favorable to the use of eggs from trans* men, more of them support the practice when it is an alternative to oocyte donation. CONCLUSION The acronym EUGIC (Extension of the Use of Gametes in Intra-Conjugal) makes it possible to group together these new situations generated by the change in the French law.
Collapse
Affiliation(s)
- M Mesnil
- IODE, UMR CNRS 6262, université de Rennes 1, Rennes, France
| | - N Ranisavljevic
- CHU de Montpellier, service de gynécologie, hôpital Arnaud-de-Villeneuve, Montpellier, France
| | - S Brouillet
- CHU de Montpellier, laboratoire de biologie de la reproduction-CECOS, hôpital Arnaud-de-Villeneuve, Montpellier, France
| | - B Ducrocq
- CHU de Lille, institut de biologie de la reproduction, CECOS Nord Lille CHRU de Lille, hôpital Calmette, Lille, France
| | - A Reignier
- Biologie de la reproduction, DPI, CECOS, CHU de Nantes, UFR médecine, université de Nantes, Inserm UMR 1064, Nantes, France
| | - C Yazbeck
- CMC Ambroise Paré Hartmann Cherest, Neuilly Sur Seine, France; Institut médical Reprogynes, 75116 Paris, France
| | - C Metzler-Guillemain
- Assistance publique-Hôpitaux de Marseille (AP-HM), pôle Femmes-Parents-Enfants, centre clinico-biologique AMP-CECOS, Marseille, France
| | - J Ohl
- AMP clinique, CHU de Strasbourg, 1, place de l'hôpital, 67091 Strasbourg cedex, France
| | - L Brunet
- Institut des sciences juridique et philosophique de La Sorbonne, université Paris 1 (UMR 8103), France
| | - H Letur
- Service de gynécologie obstétrique et médecine de la reproduction, hôpital Foch, Suresnes et service d'AMP et préservation de la fertilité - polyclinique de Navarre - Pau, France
| | - C Ravel
- CHU de Rennes, service de biologie de la reproduction-CECOS, 35000 Rennes, France.
| |
Collapse
|
8
|
Martinez G, Cappetta D, Telesca M, Urbanek K, Castaldo G, Dhellemmes M, Mele VG, Chioccarelli T, Porreca V, Barbotin AL, Boursier A, Guillou F, Coutton C, Brouillet S, De Angelis A, Berrino L, Pierantoni R, Cobellis G, Chianese R, Manfrevola F. Cytochalasin D restores nuclear size acting on F-actin and IZUMO1 localization in low-quality spermatozoa. Int J Biol Sci 2023; 19:2234-2255. [PMID: 37151878 PMCID: PMC10158014 DOI: 10.7150/ijbs.77166] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2022] [Accepted: 02/16/2023] [Indexed: 05/09/2023] Open
Abstract
In spermatozoa, the nuclear F-actin supports the acroplaxome, a subacrosomal structure involved in the correct exposure of several acrosomal membrane proteins; among them, the glycoprotein IZUMO1 is the major protein involved in sperm-oocyte fusion. Nuclear F-actin is also involved in sperm head shaping and chromosome compartmentalization. To date, few notions regarding the bivalent role of F-actin on sperm chromatin organization and IZUMO1 positioning have been reported. In our work, we characterized subcellular organization of F-actin in human high- and low-quality spermatozoa (A- and B-SPZ), respectively, showing that F-actin over-expression in sperm head of B-SPZ affected IZUMO1 localization. A correct IZUMO1 repositioning following in vitro induction of F-actin depolymerization, by cytochalasin D treatment, occurred. Interestingly, F-actin depolymerization was also associated with a correct acrosome repositioning, thus to favor a proper acrosome reaction onset, with changes in sperm nuclear size parameters and histone acetylation rate reaching high-quality conditions. In conclusion, the current work shows a key role of F-actin in the control of IZUMO1 localization as well as chromatin remodeling and acetylation events.
Collapse
Affiliation(s)
- Guillaume Martinez
- Hôpital Couple-Enfant, Centre Hospitalier Universitaire de Grenoble, UM de Génétique Chromosomique, 38000 Grenoble, France
- Genetic Epigenetic and Therapies of Infertility, Institute for Advanced Biosciences INSERM U1209, CNRS UMR5309, 38000 Grenoble, France
| | - Donato Cappetta
- Department of Experimental Medicine, University of Campania L. Vanvitelli, via Costantinopoli 16, 80138, Naples, Italy
- Department of Biological and Environmental Sciences and Technologies, University of Salento, Lecce
| | - Marialucia Telesca
- Department of Experimental Medicine, University of Campania L. Vanvitelli, via Costantinopoli 16, 80138, Naples, Italy
| | - Konrad Urbanek
- Department of Molecular Medicine and Medical Biotechnologies, University of Naples “Federico II”, Via A. Pansini 5, 80131 Naples, Italy
- CEINGE-Advanced Biotechnologies, Via G. Salvatore 486, 80131 Naples, Italy
| | - Giuseppe Castaldo
- Department of Molecular Medicine and Medical Biotechnologies, University of Naples “Federico II”, Via A. Pansini 5, 80131 Naples, Italy
- CEINGE-Advanced Biotechnologies, Via G. Salvatore 486, 80131 Naples, Italy
| | - Magali Dhellemmes
- Genetic Epigenetic and Therapies of Infertility, Institute for Advanced Biosciences INSERM U1209, CNRS UMR5309, 38000 Grenoble, France
| | - Vincenza Grazia Mele
- Department of Experimental Medicine, University of Campania L. Vanvitelli, via Costantinopoli 16, 80138, Naples, Italy
| | - Teresa Chioccarelli
- Department of Experimental Medicine, University of Campania L. Vanvitelli, via Costantinopoli 16, 80138, Naples, Italy
| | - Veronica Porreca
- Department of Experimental Medicine, University of Campania L. Vanvitelli, via Costantinopoli 16, 80138, Naples, Italy
| | - Anne-Laure Barbotin
- CHU Lille, Institute de Biologie de la Reproduction-Spermiologie-CECOS, F-59000, Lille, France
| | - Angèle Boursier
- CHU Lille, Institute de Biologie de la Reproduction-Spermiologie-CECOS, F-59000, Lille, France
| | - Florian Guillou
- CNRS, IFCE, INRAE, Université de Tours, PRC, Nouzilly, France
| | - Charles Coutton
- Hôpital Couple-Enfant, Centre Hospitalier Universitaire de Grenoble, UM de Génétique Chromosomique, 38000 Grenoble, France
- Genetic Epigenetic and Therapies of Infertility, Institute for Advanced Biosciences INSERM U1209, CNRS UMR5309, 38000 Grenoble, France
| | - Sophie Brouillet
- Université de Montpellier, EmbryoPluripotency, DEFE, INSERM 1203, Hôpital Arnaud de Villeneuve, CHRU Saint-Eloi, 80 Avenue Augustin Fliche, CEDEX 05, 34295 Montpellier, France
| | - Antonella De Angelis
- Department of Experimental Medicine, University of Campania L. Vanvitelli, via Costantinopoli 16, 80138, Naples, Italy
| | - Liberato Berrino
- Department of Experimental Medicine, University of Campania L. Vanvitelli, via Costantinopoli 16, 80138, Naples, Italy
| | - Riccardo Pierantoni
- Department of Experimental Medicine, University of Campania L. Vanvitelli, via Costantinopoli 16, 80138, Naples, Italy
| | - Gilda Cobellis
- Department of Experimental Medicine, University of Campania L. Vanvitelli, via Costantinopoli 16, 80138, Naples, Italy
| | - Rosanna Chianese
- Department of Experimental Medicine, University of Campania L. Vanvitelli, via Costantinopoli 16, 80138, Naples, Italy
- ✉ Corresponding author: Prof. Rosanna Chianese, Department of Experimental Medicine, University of Campania "Luigi Vanvitelli", Via Costantinopoli 16, 80138, Naples, Italy. Tel. Number: +39 081 5667528;
| | - Francesco Manfrevola
- Department of Experimental Medicine, University of Campania L. Vanvitelli, via Costantinopoli 16, 80138, Naples, Italy
| |
Collapse
|
9
|
Barry F, Rayssac M, Gala A, Ferrières-Hoa A, Loup V, Anahory T, Brouillet S, Hamamah S. [What issues, changes and adaptations for French ART centers in the context of the new bioethics law?]. Gynecol Obstet Fertil Senol 2022; 50:777-787. [PMID: 36096450 DOI: 10.1016/j.gofs.2022.08.005] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/10/2022] [Revised: 08/16/2022] [Accepted: 08/17/2022] [Indexed: 06/15/2023]
Abstract
OBJECTIVE This review intends to introduce the changes of the new Bioethics law in the reproductive field and its application in French ART centers. MATERIAL AND METHODS The review details the main provisions of the Bioethics Law of August 2nd 2021 as well as the three decrees published since: the first one on September 29th 2021, which specifies in particular the age conditions to benefit from ART and self-preservation of one's gametes; another decree on December 31st, 2021, to set the terms and conditions for gamete self-preservation activities for non-medical reasons and the last decree on April 14th 2022, relating to the allocation of donated gametes and embryo donation. RESULTS Since the law of August 2nd, 2021, access conditions to assisted reproductive technology (ART) have evolved in France. Previously based on pathological infertility or the risk of transmission of a serious disease, ART is now intended to respond to the parental project of a couple formed by a man and a woman, two women or an unmarried woman. With the widening of access conditions, the use of gamete donation will likely increase. The upcoming raise of children born from gamete donation has led the legislator to question their right to access their origin. From September 1st 2022, adults born from gamete donation will be able to request a special administrative authority in order to access the donor's non identifying data (age, physical characteristics, family and professional situation, motivation for the donation…) and/or the donor's identity. Moreover, the new bioethics law opens up the possibility of autologous gamete cryopreservation without medical reasons, under specific age conditions, in order to carry out an assisted reproduction technique later. If gametes are not used, autologous gamete preservation could also allow an increase in gamete donation. However, the modification of gamete donation conditions could suggest a short term decrease in donors' number. Finally, the new bioethics law further opens up research on human embryos and embryonic stem cells. CONCLUSION The arrangements introduced by the Bioethics Law promulgated on August 2nd, 2021 represent a major revolution in the field of Reproductive Medicine and are expected to transform the practices of reproductive biology centers and CECOS in France.
Collapse
Affiliation(s)
- F Barry
- UMR INSERM Développement Embryonnaire, Environnement et Fertilité (DEFE), Université de Montpellier, Montpellier, France; Département de biologie de la reproduction/DPI et CECOS, CHU Arnaud de Villeneuve Montpellier, Montpellier, France
| | - M Rayssac
- Département de biologie de la reproduction/DPI et CECOS, CHU Arnaud de Villeneuve Montpellier, Montpellier, France
| | - A Gala
- Département de biologie de la reproduction/DPI et CECOS, CHU Arnaud de Villeneuve Montpellier, Montpellier, France
| | - A Ferrières-Hoa
- Département de biologie de la reproduction/DPI et CECOS, CHU Arnaud de Villeneuve Montpellier, Montpellier, France
| | - V Loup
- Département de biologie de la reproduction/DPI et CECOS, CHU Arnaud de Villeneuve Montpellier, Montpellier, France
| | - T Anahory
- Département de biologie de la reproduction/DPI et CECOS, CHU Arnaud de Villeneuve Montpellier, Montpellier, France
| | - S Brouillet
- UMR INSERM Développement Embryonnaire, Environnement et Fertilité (DEFE), Université de Montpellier, Montpellier, France; Département de biologie de la reproduction/DPI et CECOS, CHU Arnaud de Villeneuve Montpellier, Montpellier, France
| | - S Hamamah
- UMR INSERM Développement Embryonnaire, Environnement et Fertilité (DEFE), Université de Montpellier, Montpellier, France; Département de biologie de la reproduction/DPI et CECOS, CHU Arnaud de Villeneuve Montpellier, Montpellier, France.
| |
Collapse
|
10
|
GALA A, Ferrières-Hoa A, Barry F, Brouillet S, Vintejoux E, Gaspari L, Anahory T, Hamamah S. IMPACT OF ARTIFICIAL SHRINKAGE PRIOR TO FRESH BLASTOCYST TRANSFER: A PROSPECTIVE DOUBLE BLIND RANDOMIZED CONTROLLED TRIAL. Fertil Steril 2022. [DOI: 10.1016/j.fertnstert.2022.08.414] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
11
|
Brouillet S, Ducrocq B, Mestres S, Guillemain C, Ravel C, Reignier A. [Fertility preservation and access to medically assisted reproduction for Trans people: Guidelines from French Professional Association for Transgender Health]. Gynecol Obstet Fertil Senol 2022; 50:682-688. [PMID: 35750197 DOI: 10.1016/j.gofs.2022.06.005] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/07/2022] [Revised: 06/13/2022] [Accepted: 06/15/2022] [Indexed: 06/15/2023]
Abstract
Many health care professionals are dealing with the issue of transgender people in their medical practice. In the field of reproduction, Trans people can benefit from fertility preservation before the introduction of hormonal treatment or surgery altering their fertility. This article, which is the result of a collaborative work of several reproductive professionals involved in the health of Trans people, provides an overview of the possibilities of fertility preservation and medically assisted reproduction techniques in France for Trans people.
Collapse
Affiliation(s)
- S Brouillet
- Inserm 1203 DEFE, département de biologie de la reproduction, CHU de Montpellier, université de Montpellier, Montpellier, France
| | - B Ducrocq
- CECOS, CHU de Lille, institut de biologie de la reproduction, Lille, France
| | - S Mestres
- Assistance médicale à la procréation, CECOS, CHU de Clermont-Ferrand, CHU d'Estaing, Clermont-Ferrand, France
| | - C Guillemain
- Pôle femmes-parents-enfants, centre clinicobiologique d'assistance médicale à la procréation - CECOS, APHM, hôpital La Conception, 13385 Marseille cedex 5, France
| | - C Ravel
- Inserm, service de biologie de la reproduction - CECOS, EHESP, CHU de Rennes, université Rennes, Irset (institut de recherche en santé, environnement et travail) - UMR_S 1085, 35000 Rennes, France
| | - A Reignier
- Inserm, biologie et médecine de la reproduction et gynécologie médicale, centre de recherche en transplantation et immunologie, UMR 1064, CHU de Nantes, Nantes université, Nantes, France.
| |
Collapse
|
12
|
Barry F, Benart L, Robert L, Gala A, Ferrières-Hoa A, Loup V, Anahory T, Brouillet S, Hamamah S. [HLA-C KIR interactions and placental defects: Implications in ART pregnancy issues]. Gynecol Obstet Fertil Senol 2022; 50:600-609. [PMID: 35724923 DOI: 10.1016/j.gofs.2022.06.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/19/2022] [Revised: 06/05/2022] [Accepted: 06/07/2022] [Indexed: 06/15/2023]
Abstract
OBJECTIVE The aim of this review is to update data concerning the impact of HLA-C KIR system on placental disorders and assess the involvement on ART clinical outcomes. METHOD Ensuring the maintenance of human pregnancy requires the set up of immunological tolerance to prevent foetus rejection. This phenomenon involves different actors of the immune system: among them, uterine NK cells (uNK) hold specific KIR (killer-cell immunoglobulin-like) receptors linking to HLA molecules on the surface of trophoblastic cells at implantation. Many studies provided evidence that the specific interaction between maternal KIR and foetal HLA-C could influence the process of placentation; according to the KIR haplotype and the type of HLA-C, the interaction could be detrimental for placental function. We reviewed the latest data available regarding HLA-C KIR interactions and ART outcomes. RESULTS The available results highlight a significant increase of preeclampsia risk and recurrent miscarriages when the maternal inhibitory haplotype KIR AA is present, this risk is all the more enhanced when the interaction occurs with foetal HLA-C2. Recent data suggest the consequences of this detrimental interaction in case of DET (double embryo transfer) or use of donor's oocytes in ART practice. On the other hand, maternal KIR AB or BB haplotypes haven't been related to an additional obstetrical risk, as well as the foetal HLA-C1 homozygous allotype. CONCLUSION Despite the existence of many confoundings in current literature on the subject, interaction between maternal KIR and foetal HLA-C represent a promising target lead to broaden the spectrum of placental defects etiologies, especially in the reproductive health area.
Collapse
Affiliation(s)
- F Barry
- UMR Inserm DEFE 1203, développement embryonnaire, fertilité et environnement, université de Montpellier, Montpellier, France; Département de Biologie de la Reproduction et CECOS, unité AMP/DPI, CHU Arnaud de Villeneuve, Montpellier, France
| | - L Benart
- Département de Biologie de la Reproduction et CECOS, unité AMP/DPI, CHU Arnaud de Villeneuve, Montpellier, France
| | - L Robert
- Département de Biologie de la Reproduction et CECOS, unité AMP/DPI, CHU Arnaud de Villeneuve, Montpellier, France
| | - A Gala
- UMR Inserm DEFE 1203, développement embryonnaire, fertilité et environnement, université de Montpellier, Montpellier, France; Département de Biologie de la Reproduction et CECOS, unité AMP/DPI, CHU Arnaud de Villeneuve, Montpellier, France
| | - A Ferrières-Hoa
- UMR Inserm DEFE 1203, développement embryonnaire, fertilité et environnement, université de Montpellier, Montpellier, France; Département de Biologie de la Reproduction et CECOS, unité AMP/DPI, CHU Arnaud de Villeneuve, Montpellier, France
| | - V Loup
- Département de Biologie de la Reproduction et CECOS, unité AMP/DPI, CHU Arnaud de Villeneuve, Montpellier, France
| | - T Anahory
- Département de Biologie de la Reproduction et CECOS, unité AMP/DPI, CHU Arnaud de Villeneuve, Montpellier, France
| | - S Brouillet
- UMR Inserm DEFE 1203, développement embryonnaire, fertilité et environnement, université de Montpellier, Montpellier, France; Département de Biologie de la Reproduction et CECOS, unité AMP/DPI, CHU Arnaud de Villeneuve, Montpellier, France
| | - S Hamamah
- UMR Inserm DEFE 1203, développement embryonnaire, fertilité et environnement, université de Montpellier, Montpellier, France; Département de Biologie de la Reproduction et CECOS, unité AMP/DPI, CHU Arnaud de Villeneuve, Montpellier, France.
| |
Collapse
|
13
|
Duraes M, Rathat G, Bringer-Deutsch S, Ranisavljevic N, Brouillet S, Defez-Fougeron C, Duflos C. Fertility preservation in patients of childbearing age treated for breast cancer: A nationwide cohort study. Breast 2022; 64:121-126. [PMID: 35661841 PMCID: PMC9163100 DOI: 10.1016/j.breast.2022.05.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2022] [Revised: 05/12/2022] [Accepted: 05/27/2022] [Indexed: 11/19/2022] Open
Abstract
Background Approximately 7% of breast cancers are diagnosed in women under 40. Question of subsequent fertility has become fundamental. We aimed to evaluate the rate of fertility preservation (FP) by oocyte retrieval (OR) after ovarian stimulation in patients of childbearing age, managed for breast cancer with adjuvant chemotherapy in France, reuse rate of frozen gametes and live births rate (LBR) after treatment. Methods We included 15,774 women between 18 and 40 years old, managed by surgery and adjuvant chemotherapy for breast cancer, between January 2011 and December 2020 from a French health registry. Patients with OR after breast surgery and before chemotherapy were considered as FP group; those with no OR as no FP group. To compare LBR with French population independently of age, we calculated Standardized Incidence Rates (SIR) of live births using indirect standardization method. Results FP rate increased gradually since 2011, reaching 17% in 2019. A decrease in use was observed in 2020 (13,9%). Among patients with at least 2 years of follow-up, gamete reuse rate was 5,6%. Births after cancer were mostly from spontaneous pregnancies. Among patients with at least 3 years of follow-up, LBR was 19,6% in FP group, 3,9% in second group. SIR of live births was of 1,05 (95% CI = 0.91–1.19) and 0.33 (95% CI = 0.30–0.36) in FP and no FP group respectively. Conclusion Oncofertility activity increased until 2019 in France, reaching 17%. Gamete reuse rate was low. Births resulted mainly from spontaneous pregnancies. SIR of live births was lower in no FP group. Fertility preservation rate increased gradually since 2011, reaching 17% in 2019. Among patients with at least 2 years of follow-up, gamete reuse rate was 5,6%. Births after breast cancer were mostly from spontaneous pregnancies. Life births rate was 19,6% in fertility preservation group, 3,9% in second group.
Collapse
Affiliation(s)
- Martha Duraes
- Department of Gynecological and Breast Surgery, Montpellier University Hospital, Montpellier, France.
| | - Gauthier Rathat
- Department of Gynecological and Breast Surgery, Montpellier University Hospital, Montpellier, France
| | - Sophie Bringer-Deutsch
- Department of Obstetrics, Gynecology and Reproductive Medicine, Montpellier University Hospital, Montpellier, France
| | - Noémie Ranisavljevic
- Department of Obstetrics, Gynecology and Reproductive Medicine, Montpellier University Hospital, Montpellier, France
| | - Sophie Brouillet
- Department of Reproductive Biology, Montpellier University Hospital, Montpellier, France
| | | | - Claire Duflos
- Clinical Research and Epidemiology Unit, Montpellier University Hospital, Montpellier, France
| |
Collapse
|
14
|
Gala A, Ferrières-Hoa A, Barry F, Brouillet S, Vintejoux E, Gaspari L, Anahory T, Hamamah S. P-219 Does artificial shrinkage prior to fresh blastocyst transfer improve ongoing pregnancy rate? A prospective double blind randomized controlled trial. Hum Reprod 2022. [DOI: 10.1093/humrep/deac107.212] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Study question
Does artificial shrinkage (AS) of blastocoelic cavity (BC) prior to fresh elective single blastocyst transfer (SBET) increase ongoing pregnancy rate?
Summary answer
Ongoing pregnancy rates were similar with or without AS of blastocoelic cavity. AS does not seem to provide benefit before fresh blastocyst transfer.
What is known already
AS of the vitrified blastocysts enhances success rate in frozen embryo transfer cycles.
In vitro cultured embryos suffer changes in temperature, pH and osmotic pressure. Moreover, manipulations such as pipetting, fertilization, microscopic observations and changes of dishes can induce oxidative stress and apoptosis. The presence of cell free DNA (cfDNA) in blastocyst fluids could be the consequence of its release from dead cells. The quantity of cfDNA in blastocyst fluids could possibly be related to the rate of cell death. It is thus interesting to estimate whether AS of BC could improve the implantation rate in cycles with fresh blastocyst transfer.
Study design, size, duration
Prospective, randomized, double blind controlled study. From May 20th 2018 to June 30th 2021, 150 couples elected for fresh SBET were included in the study and were randomly selected as “AS +” group (n = 100), where AS of blastocoel was performed by laser pulse before fresh blastocyst transfer, and “AS -” group (n = 50), where fresh blastocysts were transferred without any additional intervention.
Participants/materials, setting, methods
On day 5 after fertilization, one blastocyst with a grade of expansion B3, B4, B5 or B6 and type A or B quality trophectoderm (Gardner and Schoolcraft classification, 1999) was selected for transfer. After replacement, the droplet that contained the embryo from day 3 was collected for cfDNA level quantification.
Ongoing pregnancy rate was determined by the visualization of a gestational sac with a foetal heartbeat 6 weeks later and cfDNA was assessed by ALU-qPCR.
Main results and the role of chance
The two groups were similar for age, BMI, infertility duration and cause, stimulation characteristics and embryological parameters. The global ongoing pregnancy rate per transfer after SBET was 49.7 %. The pregnancy rate in the AS + group was slightly higher than in the control group but not significantly (respectively 50.00 % and 48,9 %, p = 0,91).
cfDNA median value in the AS+ group was comparable to the control group (0.493 (0.219; 0.915) mg/ml and 0.595 (0.271; 1.129) mg/ml respectively (p = 0.45)). No link was found between cfDNA rate and clinical pregnancy rate.
Limitations, reasons for caution
Patients included in the study are still followed to evaluate the impact of AS on live birth rate, wastage rate, obstetrical and neonatal complications. cfDNA rate was evaluated in spent culture media and not by blastocentesis, which could provide a more accurate quantification.
Wider implications of the findings
To our knowledge, this is the first prospective randomized controlled study assessing the benefit of AS of BC before fresh blastocyst transfer. The inclusion of live birth rate is crucial to ascertain the interest of this technique and more studies are needed to improve the use of cfDNA in routine.
Trial registration number
NCT02988544
Collapse
Affiliation(s)
- A Gala
- Hôpital Arnaud de Villeneuve, Assisted Reproductive Technology Department , Montpellier Cédex 5, France
- Inserm 1203, Irbm , Montpellier, France
| | - A Ferrières-Hoa
- Hôpital Arnaud de Villeneuve, Assisted Reproductive Technology Department , Montpellier Cédex 5, France
- Inserm 1203, Irbm , Montpellier, France
| | - F Barry
- Hôpital Arnaud de Villeneuve, Assisted Reproductive Technology Department , Montpellier Cédex 5, France
- Inserm 1203, Irbm , Montpellier, France
| | - S Brouillet
- Hôpital Arnaud de Villeneuve, Assisted Reproductive Technology Department , Montpellier Cédex 5, France
- Inserm 1203, Irbm , Montpellier, France
| | - E Vintejoux
- Hôpital Arnaud de Villeneuve, Assisted Reproductive Technology Department , Montpellier Cédex 5, France
| | - L Gaspari
- Inserm 1203, Irbm , Montpellier, France
| | - T Anahory
- Hôpital Arnaud de Villeneuve, Assisted Reproductive Technology Department , Montpellier Cédex 5, France
| | - S Hamamah
- Hôpital Arnaud de Villeneuve, Assisted Reproductive Technology Department , Montpellier Cédex 5, France
- Inserm 1203, Irbm , Montpellier, France
| |
Collapse
|
15
|
Brouillet S, Baron C, Barry F, Andreeva A, Haouzi D, Gala A, Ferrières-Hoa A, Loup V, Anahory T, Ranisavljevic N, Gaspari L, Hamamah S. Author Correction: Biphasic (5-2%) oxygen concentration strategy significantly improves the usable blastocyst and cumulative live birth rates in in vitro fertilization. Sci Rep 2022; 12:7580. [PMID: 35534533 PMCID: PMC9085757 DOI: 10.1038/s41598-022-11988-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Affiliation(s)
- Sophie Brouillet
- INSERM 1203, Développement Embryonnaire Fertilité Environnement, Univ Montpellier, Montpellier, France. .,CHU Montpellier, Département de Biologie de la Reproduction, Biologie de la Reproduction/DPI et CECOS, Univ Montpellier, Montpellier, France.
| | - Chloé Baron
- INSERM 1203, Développement Embryonnaire Fertilité Environnement, Univ Montpellier, Montpellier, France
| | - Fatima Barry
- INSERM 1203, Développement Embryonnaire Fertilité Environnement, Univ Montpellier, Montpellier, France.,CHU Montpellier, Département de Biologie de la Reproduction, Biologie de la Reproduction/DPI et CECOS, Univ Montpellier, Montpellier, France
| | - Aneta Andreeva
- CHU Montpellier, Département de Biologie de la Reproduction, Biologie de la Reproduction/DPI et CECOS, Univ Montpellier, Montpellier, France
| | - Delphine Haouzi
- INSERM 1203, Développement Embryonnaire Fertilité Environnement, Univ Montpellier, Montpellier, France.,CHU Montpellier, Département de Biologie de la Reproduction, Biologie de la Reproduction/DPI et CECOS, Univ Montpellier, Montpellier, France
| | - Anna Gala
- INSERM 1203, Développement Embryonnaire Fertilité Environnement, Univ Montpellier, Montpellier, France.,CHU Montpellier, Département de Biologie de la Reproduction, Biologie de la Reproduction/DPI et CECOS, Univ Montpellier, Montpellier, France
| | - Alice Ferrières-Hoa
- INSERM 1203, Développement Embryonnaire Fertilité Environnement, Univ Montpellier, Montpellier, France.,CHU Montpellier, Département de Biologie de la Reproduction, Biologie de la Reproduction/DPI et CECOS, Univ Montpellier, Montpellier, France
| | - Vanessa Loup
- CHU Montpellier, Département de Biologie de la Reproduction, Biologie de la Reproduction/DPI et CECOS, Univ Montpellier, Montpellier, France
| | - Tal Anahory
- CHU Montpellier, Département de Biologie de la Reproduction, Biologie de la Reproduction/DPI et CECOS, Univ Montpellier, Montpellier, France
| | - Noémie Ranisavljevic
- CHU Montpellier, Département de Biologie de la Reproduction, Biologie de la Reproduction/DPI et CECOS, Univ Montpellier, Montpellier, France
| | - Laura Gaspari
- INSERM 1203, Développement Embryonnaire Fertilité Environnement, Univ Montpellier, Montpellier, France.,CHU Montpellier, Unité d'Endocrinologie-Gynécologie Pédiatrique, Service de Pédiatrie, Univ Montpellier, Montpellier, France
| | - Samir Hamamah
- INSERM 1203, Développement Embryonnaire Fertilité Environnement, Univ Montpellier, Montpellier, France.,CHU Montpellier, Département de Biologie de la Reproduction, Biologie de la Reproduction/DPI et CECOS, Univ Montpellier, Montpellier, France
| |
Collapse
|
16
|
du Boulet B, Ranisavljevic N, Mollevi C, Bringer-Deutsch S, Brouillet S, Anahory T. Individualized luteal phase support based on serum progesterone levels in frozen-thawed embryo transfer cycles maximizes reproductive outcomes in a cohort undergoing preimplantation genetic testing. Front Endocrinol (Lausanne) 2022; 13:1051857. [PMID: 36531476 PMCID: PMC9755854 DOI: 10.3389/fendo.2022.1051857] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/23/2022] [Accepted: 11/14/2022] [Indexed: 12/04/2022] Open
Abstract
INTRODUCTION Low serum progesterone concentration on frozen embryo transfer (FET) day in hormone replacement therapy (HRT) cycles results in lower reproductive outcomes. Recent studies showed the efficiency of a "rescue protocol'' to restore reproductive outcomes in these patients. Here, we compared reproductive outcomes in HRT FET cycles in women with low serum progesterone levels who received individualized luteal phase support (iLPS) and in women with adequate serum progesterone levels who underwent in vitro fertilization for pre-implantation genetic testing for structural rearrangements or monogenic disorders. DESIGN This retrospective cohort study included women (18-43 years of age) undergoing HRT FET cycles with pre-implantation genetic testing at Montpellier University Hospital between June 2020 and May 2022. A standard HRT was used: vaginal micronized estradiol (6mg/day) followed by vaginal micronized progesterone (VMP; 800 mg/day). Serum progesterone was measured after four doses of VMP: if <11ng/ml, 25mg/day subcutaneous progesterone or 30mg/day oral dydrogesterone was introduced. RESULTS 125 HRT FET cycles were performed in 111 patients. Oral/subcutaneous progesterone supplementation concerned 39 cycles (n=20 with subcutaneous progesterone and n=19 with oral dydrogesterone). Clinical and laboratory parameters of the cycles were comparable between groups. The ongoing pregnancy rate (OPR) was 41.03% in the supplemented group and 18.60% in the non-supplemented group (p= 0.008). The biochemical pregnancy rate and miscarriages rate tended to be higher in the non-supplemented group versus the supplemented group: 13.95% versus 5.13% and 38.46% versus 15.79% (p=0.147 and 0.182 respectively). Multivariate logistic regression analysis found that progesterone supplementation was significantly associated with higher OPR (adjusted OR = 3.25, 95% CI [1.38 - 7.68], p=0.007). CONCLUSION In HRT FET cycles, progesterone supplementation in patients with serum progesterone concentration <11 ng/mL after four doses of VMP significantly increases the OPR.
Collapse
Affiliation(s)
- Bertille du Boulet
- Department of Reproductive Medicine, Montpellier University Hospital, University of Montpellier, Montpellier, France
- *Correspondence: Bertille du Boulet,
| | - Noemie Ranisavljevic
- Department of Reproductive Medicine, Montpellier University Hospital, University of Montpellier, Montpellier, France
| | - Caroline Mollevi
- Institute Desbrest of Epidemiology and Public Health, Montpellier University Hospital, University of Montpellier, INSERM, Montpellier, France
| | - Sophie Bringer-Deutsch
- Department of Reproductive Medicine, Montpellier University Hospital, University of Montpellier, Montpellier, France
| | - Sophie Brouillet
- Department of Reproductive Biology-CECOS, Montpellier University Hospital, University of Montpellier, Montpellier, France
- Embryo Development Fertility Environment, University of Montpellier, INSERM 1203, Montpellier, France
| | - Tal Anahory
- Department of Reproductive Medicine, Montpellier University Hospital, University of Montpellier, Montpellier, France
| |
Collapse
|
17
|
Mauries C, Ranisavljevic N, Mollevi C, Brunet C, Hamamah S, Brouillet S, Anahory T. "Short agonist stop" protocol, an ovarian stimulation for poor responders in in vitro fertilization (IVF): A pilot study. Front Endocrinol (Lausanne) 2022; 13:1056520. [PMID: 36465628 PMCID: PMC9714551 DOI: 10.3389/fendo.2022.1056520] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/28/2022] [Accepted: 10/26/2022] [Indexed: 11/18/2022] Open
Abstract
INTRODUCTION Poor responder patients remain a challenge in assisted reproductive technologies. The "short agonist stop" (SAS) stimulation protocol uses a double stimulation (flare up effect with the gonadotropin-releasing hormone (GnRH) agonist (GnRH-a) then gonadotropins) associated with a less strenuous blockage (discontinuation of GnRH-a) to favor follicular recruitment in order to obtain a better ovarian response. This study aims to compare the number of oocytes obtained after a SAS stimulation protocol with those obtained after the previous stimulation protocol, in the same women, with poor ovarian response (POR) diagnosed according to the POSEIDON criteria. DESIGN This therapeutic observational retrospective cohort from 2018 to 2022, with a case-control evaluation compared with the same patients' previous performance, included women with POR undergoing IVF with SAS stimulation protocol. The primary outcome was the number of total oocytes recovered and secondary outcomes were the numbers of mature oocytes, total embryos observed at day 2 and usable cleaved embryos and blastocysts (day 5/6). RESULTS 63 patients with SAS and previous cycles were included. In the SAS group, the mean number of oocytes was significantly higher: 7.3 vs 5.7, p=0.018 in comparison with the previous attempt. So was the number of mature oocytes (5.8 vs 4.1, p=0.032) and the total mean number of embryos obtained at day 2 (4.1 versus 2.7, p=0.016). The SAS stimulation generated 84 usable embryos: 57 cleaved embryos and 27 blastocysts. The mean number of usable embryos was similar in both groups (1.64 vs 1.31, respectively, p=0.178). In total, out of 63 patients, after the SAS protocol, and subsequent embryo transfers (fresh and frozen, n=54), 9 patients had ongoing pregnancies and no miscarriage occurred. The cumulative ongoing pregnancy rate (cOPR) after the SAS protocol was 14.3% (9/63) per oocyte pick-up and 16.7% (9/54) per transfer. CONCLUSION SAS stimulation is a short and original protocol strengthening the therapeutic arsenal of poor responders, that may offer promising results for those patients with low prognosis and previous failed IVF. Results must be confirmed with a randomized controlled trial.
Collapse
Affiliation(s)
- Charlotte Mauries
- Department of Reproductive Medicine, Montpellier University Hospital, University of Montpellier, Montpellier, France
- *Correspondence: Charlotte Mauriès,
| | - Noemie Ranisavljevic
- Department of Reproductive Medicine, Montpellier University Hospital, University of Montpellier, Montpellier, France
| | - Caroline Mollevi
- Institute Desbrest of Epidemiology and Public Health, Montpellier University Hospital, University of Montpellier, INSERM, Montpellier, France
| | - Cecile Brunet
- Department of Reproductive Medicine, Montpellier University Hospital, University of Montpellier, Montpellier, France
| | - Samir Hamamah
- Department of Reproductive Biology-CECOS, Montpellier University Hospital, University of Montpellier, Montpellier, France
- Embryo Development Fertility Environment, University of Montpellier, INSERM 1203, Montpellier, France
| | - Sophie Brouillet
- Department of Reproductive Biology-CECOS, Montpellier University Hospital, University of Montpellier, Montpellier, France
- Embryo Development Fertility Environment, University of Montpellier, INSERM 1203, Montpellier, France
| | - Tal Anahory
- Department of Reproductive Medicine, Montpellier University Hospital, University of Montpellier, Montpellier, France
| |
Collapse
|
18
|
Haouzi D, Entezami F, Tuaillon E, Gala A, Ferrières-Hoa A, Brouillet S, Thierry AR, Hamamah S. SARS-CoV-2 and Implantation Window: Gene Expression Mapping of Human Endometrium and Preimplantation Embryo. Life (Basel) 2021; 11:life11121378. [PMID: 34947909 PMCID: PMC8706202 DOI: 10.3390/life11121378] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2021] [Revised: 12/03/2021] [Accepted: 12/09/2021] [Indexed: 11/16/2022] Open
Abstract
Understanding whether SARS-CoV-2 could infect cells and tissues handled during ART is crucial for risk mitigation, especially during the implantation window when either endometrial biopsies are often practiced for endometrial receptivity assessment or embryo transfer is performed. To address this question, this review analyzed current knowledge of the field and retrospectively examined the gene expression profiles of SARS-CoV-2-associated receptors and proteases in a cohort of ART candidates using our previous Affymetrix microarray data. Human endometrial tissue under natural and controlled ovarian stimulation cycles and preimplantation embryos were analyzed. A focus was particularly drawn on the renin-angiotensin system, which plays a prominent role in the virus infection, and we compared the gene expression levels of receptors and proteases related to SARS-CoV-2 infection in the samples. High prevalence of genes related to the ACE2 pathway during both cycle phases and mainly during the mid-secretory phase for ACE2 were reported. The impact of COS protocols on endometrial gene expression profile of SARS-CoV-2-associated receptors and proteases is minimal, suggesting no additional potential risks during stimulated ART procedure. In blastocysts, ACE2, BSG, CTSL, CTSA and FURIN were detectable in the entire cohort at high expression level. Specimens from female genital tract should be considered as potential targets for SARS-CoV-2, especially during the implantation window.
Collapse
Affiliation(s)
- Delphine Haouzi
- Univ Montpellier, INSERM U1203, DEFE, 34295 Montpellier, France; (D.H.); (F.E.); (A.G.); (A.F.-H.); (S.B.)
- IRMB (Institute for Regenerative Medicine & Biotherapy), Univ Montpellier, INSERM, 34295 Montpellier, France
- CHU Montpellier, ART/PGD Department, Arnaud de Villeneuve Hospital, 34295 Montpellier, France
- Global ART Innovation Network, IRMB, CHU Montpellier, 34295 Montpellier, France
| | - Frida Entezami
- Univ Montpellier, INSERM U1203, DEFE, 34295 Montpellier, France; (D.H.); (F.E.); (A.G.); (A.F.-H.); (S.B.)
- ART Department, American Hospital of Paris, 92200 Neuilly-Sur-Seine, France
| | - Edward Tuaillon
- CHU Montpellier, Bacteriology-Virology Department, 34295 Montpellier, France;
| | - Anna Gala
- Univ Montpellier, INSERM U1203, DEFE, 34295 Montpellier, France; (D.H.); (F.E.); (A.G.); (A.F.-H.); (S.B.)
- CHU Montpellier, ART/PGD Department, Arnaud de Villeneuve Hospital, 34295 Montpellier, France
| | - Alice Ferrières-Hoa
- Univ Montpellier, INSERM U1203, DEFE, 34295 Montpellier, France; (D.H.); (F.E.); (A.G.); (A.F.-H.); (S.B.)
- CHU Montpellier, ART/PGD Department, Arnaud de Villeneuve Hospital, 34295 Montpellier, France
| | - Sophie Brouillet
- Univ Montpellier, INSERM U1203, DEFE, 34295 Montpellier, France; (D.H.); (F.E.); (A.G.); (A.F.-H.); (S.B.)
- IRMB (Institute for Regenerative Medicine & Biotherapy), Univ Montpellier, INSERM, 34295 Montpellier, France
- CHU Montpellier, ART/PGD Department, Arnaud de Villeneuve Hospital, 34295 Montpellier, France
| | - Alain R. Thierry
- Regional Institute of Cancer of Montpellier, 34090 Montpellier, France;
| | - Samir Hamamah
- Univ Montpellier, INSERM U1203, DEFE, 34295 Montpellier, France; (D.H.); (F.E.); (A.G.); (A.F.-H.); (S.B.)
- IRMB (Institute for Regenerative Medicine & Biotherapy), Univ Montpellier, INSERM, 34295 Montpellier, France
- CHU Montpellier, ART/PGD Department, Arnaud de Villeneuve Hospital, 34295 Montpellier, France
- Global ART Innovation Network, IRMB, CHU Montpellier, 34295 Montpellier, France
- Correspondence: ; Tel.: +33-04-67-33-64-04; Fax: +33-04-67-33-62-90
| |
Collapse
|
19
|
Nobre Meirinhos J, Vattaire M, Barry F, Denjean L, Bouricha M, Gala A, Ferrières-Hoa A, Loup V, Gaspari L, Brouillet S, Hamamah S. [Impact of SARS-CoV-2 on fertility, gametes' quality and Assisted Reproduction Technology]. ACTA ACUST UNITED AC 2021; 50:173-181. [PMID: 34506995 PMCID: PMC8423662 DOI: 10.1016/j.gofs.2021.09.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/01/2021] [Indexed: 11/27/2022]
Abstract
Le contexte actuel de pandémie conduit à s’interroger sur les conséquences de la COVID-19 en Assistance médicale à la procréation (AMP). En effet, suite aux premières recommandations de l’Agence de la biomédecine en mars 2020, les centres d’AMP ont suspendu leurs activités. La reprise progressive des tentatives en mai 2020 s’est accompagnée de nombreux questionnements, concernant les effets directs et indirects du SARS-CoV-2 sur la qualité des gamètes, la gamétogenèse, la fertilité, la grossesse et la santé néonatale. L’objectif de cette revue de la littérature est de synthétiser les données disponibles, pour informer les patient(e)s pris(es) en charge et adapter les pratiques d’AMP en cette période de la COVID-19. La plupart des études récentes se basent sur l’évaluation des effets du syndrome infectieux, sur l’analyse des facteurs hormonaux, et sur l’expression des protéines d’entrée virale (ACE2 et TMPRSS2) au niveau des cellules impliquées dans la gamétogenèse pour évaluer les répercussions de la COVID-19. La transmission materno-fœtale du SARS-CoV-2 n’a pas pu être démontrée à ce jour, mais l’infection néonatale reste possible. Néanmoins, les hommes seraient plus à risque d’être infectés par le SARS-CoV-2, d’être symptomatiques et la spermatogenèse est vraisemblablement affectée. La présence du virus dans le sperme est un évènement rare, mais l’ensemble de ces paramètres sont à prendre en compte dans la prise en charge des couples en AMP. Cependant, aucune conséquence sur la qualité des gamètes féminins n’a été mise en évidence jusqu’à présent.
Collapse
Affiliation(s)
- Julie Nobre Meirinhos
- Département de biologie de la reproduction, biologie de la reproduction/DPI et CECOS, CHU d'Arnaud de Villeneuve Montpellier, université de Montpellier, Montpellier, France
| | - Margot Vattaire
- Département de biologie de la reproduction, biologie de la reproduction/DPI et CECOS, CHU d'Arnaud de Villeneuve Montpellier, université de Montpellier, Montpellier, France
| | - Fatima Barry
- Département de biologie de la reproduction, biologie de la reproduction/DPI et CECOS, CHU d'Arnaud de Villeneuve Montpellier, université de Montpellier, Montpellier, France
| | - Louise Denjean
- Département de biologie de la reproduction, biologie de la reproduction/DPI et CECOS, CHU d'Arnaud de Villeneuve Montpellier, université de Montpellier, Montpellier, France
| | - Molka Bouricha
- Département de biologie de la reproduction, biologie de la reproduction/DPI et CECOS, CHU d'Arnaud de Villeneuve Montpellier, université de Montpellier, Montpellier, France
| | - Anna Gala
- Département de biologie de la reproduction, biologie de la reproduction/DPI et CECOS, CHU d'Arnaud de Villeneuve Montpellier, université de Montpellier, Montpellier, France
| | - Alice Ferrières-Hoa
- Département de biologie de la reproduction, biologie de la reproduction/DPI et CECOS, CHU d'Arnaud de Villeneuve Montpellier, université de Montpellier, Montpellier, France
| | - Vanessa Loup
- Département de biologie de la reproduction, biologie de la reproduction/DPI et CECOS, CHU d'Arnaud de Villeneuve Montpellier, université de Montpellier, Montpellier, France
| | - Laura Gaspari
- Inserm 1203, développement embryonnaire précoce humain et pluripotence, Embryopluripotency, université de Montpellier, Montpellier, France; Service de pédiatrie, unité d'endocrinologie-gynécologie pédiatrique, CHU d'Arnaud de Villeneuve Montpellier, université de Montpellier, Montpellier, France
| | - Sophie Brouillet
- Inserm 1203, développement embryonnaire précoce humain et pluripotence, Embryopluripotency, université de Montpellier, Montpellier, France; Département de biologie de la reproduction, biologie de la reproduction/DPI et CECOS, CHU d'Arnaud de Villeneuve Montpellier, université de Montpellier, Montpellier, France
| | - Samir Hamamah
- Inserm 1203, développement embryonnaire précoce humain et pluripotence, Embryopluripotency, université de Montpellier, Montpellier, France; Département de biologie de la reproduction, biologie de la reproduction/DPI et CECOS, CHU d'Arnaud de Villeneuve Montpellier, université de Montpellier, Montpellier, France.
| |
Collapse
|
20
|
Entezami F, Haouzi D, Brouillet S, Barry F, Gala A, Hamamah S. FEMALE GAMETE AND HUMAN EMBRYO SUSCEPTIBILITY TO SARS-COV-2. Fertil Steril 2021. [PMCID: PMC8446872 DOI: 10.1016/j.fertnstert.2021.07.803] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
21
|
Haouzi D, Entezami F, Brouillet S, Barry F, Gala A, Hamamah S. ANALYZE OF THE GENE EXPRESSION PROFILES OF SARS-COV-2-ASSOCIATED RECEPTORS AND PROTEASES IN HUMAN ENDOMETRIUM DURING ART PRACTICE. Fertil Steril 2021. [PMCID: PMC8446868 DOI: 10.1016/j.fertnstert.2021.07.826] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
22
|
Haouzi D, Entezami F, Brouillet S, Barry F, Gala A, Ferrieres-Hoa A, Tal A, Hamamah S. O-141 Mapping of SARS-CoV-2-associated receptors and proteases mRNA in human endometrium during natural and stimulated cycles. Hum Reprod 2021. [PMCID: PMC8385900 DOI: 10.1093/humrep/deab127.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Study question Covid-19 pandemic has significantly affected the assisted reproductive technology (ART) practice. Understanding whether SARS-CoV-2 could infect endometrial tissues during ART is crucial for risk mitigation Summary answer Analyses of gene expression profiles of SARS-CoV-2 host entry candidates from microarray data suggest that endometrium should be considered as potential target for SARS-CoV-2 infection. What is known already Very few studies analyzed the gene expression profiles of SARS-CoV-2-associated receptors and proteases, mainly focusing on ACE2 and TMPRSS2 expression, resulting incomplete knowledge in different specimens from female genital tract. However, no studies have analyzed the potential impact of controlled ovarian stimulation (COS) protocols during ART procedure on the endometrial gene expression profiles of SARS-CoV-2-associated receptors and proteases Study design, size, duration To address this question, we retrospectively examined the gene expression profile of SARS-CoV-2-associated receptors and proteases in endometrial biopsies of a cohort of ART candidates using Affymetrix microarray data Participants/materials, setting, methods Human endometrial tissue under natural (n = 62) and COS cycles (n = 42) were analyzed. A focus was particularly made on the renin-angiotensin system relates genes with a prominent role in the virus infection, and gene expression levels of receptors and proteases closely related to SARS-CoV-2 infectionwas also studied. Main results and the role of chance Using our large cohort of endometrial samples, we reported a high prevalence of genes related to the ACE2 pathway, including AGT, AGTR1, ANPEP, CTSA, ENPEP, LNPEP, MME, NLN, THOP1, BSG and CTSL during both phases(early- and mid-secretory phase), and mainly during the mid-secretory phase for ACE2. The highest signal intensities were found for CTSA, LNPEP, MME, NLN, BSG and CTSL. The most representative of dual coexpression of SARS-CoV-2-associated receptor and protease in endometrium was BSG-CSTL and BSG-CTSA. It s also important to note high variation of SARS-CoV-2 receptors inter-patients under natural cycle.Globally, the impact of COS on endometrial gene expression profile of SARS-CoV-2-associated receptors and proteases of non Covid-19 patients is low, suggesting no additional potential risks of SARS-CoV-2 infection during stimulated ART procedure compared with natural cycles. Limitations, reasons for caution Analyses of Affymetrix microarray gene expression data were performed in non-COVID-19 patients. Whether the SARS-CoV-2 infection changes the endometrial gene expression profile of SARS-CoV-2-associated receptors and proteases is under investigation Wider implications of the findings Specimens from female genital tract may be considered as potential targets for SARS-CoV-2. Trial registration number not applicable
Collapse
Affiliation(s)
- D Haouzi
- INSERM U1203, IRMB- Hôpital St-Eloi- CHRU Montpellier, MONTPELLIER, France
| | - F Entezami
- American Hospital of Paris, ART department, Neuilly-Sur-Seine, France
| | - S Brouillet
- IRMB- Inserm U1203, Hôpital St-Eloi- CHRU Montpellier, Montpellier, France
| | - F Barry
- IRMB- Inserm U1203, Hôpital St-Eloi- CHRU Montpellier, Montpellier, France
| | - A Gala
- IRMB- Inserm U1203, Hôpital St-Eloi- CHRU Montpellier, Montpellier, France
| | - A Ferrieres-Hoa
- IRMB- Inserm U1203, Hôpital St-Eloi- CHRU Montpellier, Montpellier, France
| | - A Tal
- CHU and University of Montpellier, Department of Reproductive Medicine, Montpellier, France
| | - S Hamamah
- IRMB- Inserm U1203, Hôpital St-Eloi- CHRU Montpellier, Montpellier, France
| |
Collapse
|
23
|
Entezami F, Haouzi D, Brouillet S, Barry F, Gala A, Ferrieres-Hoa A, Hamamah S. P–242 Gene expression profiles of SARS-CoV–2-associated receptors and proteases in human early embryonic development and follicular cells. Hum Reprod 2021. [PMCID: PMC8385899 DOI: 10.1093/humrep/deab130.241] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Study question
Are the oocytes, embryos, granulosa and cumulus cells, used during ART, susceptible to the SARS-CoV–2 infection?
Summary answer
Transcriptomic analyses of SARS-CoV–2-associated receptors and proteases strongly suggest that blastocysts are most permissive to SARS-CoV–2 compared with mature oocytes and day 3 embryos.
What is known already
Very few studies analyzed the gene expression profiles of SARS-CoV–2-associated receptors and proteases, mainly focusing on ACE2 and TMPRSS2 expression, resulting in partial knowledge in different specimens from female genital tract. To date, the gene expression profile of SARS-CoV–2 host entry candidates in the entire preimplantation embryos is scarcely available. Moreover, reports on oocyte and granulosa cells susceptibilityto SARS-CoV–2 are very sparse.
Study design, size, duration
To address this question, we retrospectively examined the gene expression profiles of SARS-CoV–2-associated receptors and proteases in human granulosa cells (GCs), cumulus cells (CCs), mature oocytes, day 3 embryos, blastocysts and trophectoderm cells obtained from our previously described Affymetrix microarray data.
Participants/materials, setting, methods
Human GCs and CCs (n = 17), mature oocytes (n = 6), and preimplantation embryos (n = 20) were analyzed. The comparison of gene expression levels of receptors and proteases closely related to SARS-CoV–2 infection. For each gene, the number of samples with the probe set ‘present’, based on the detection call, was analyzed. Each probe set was classified according to the signal intensity value median, as low (<100), medium (100–200) or high expression level (>200).
Main results and the role of chance
ACE2, BSG, CTSL, CTSA were detectable at high expression level in all mature oocyte samples, while only CTSL was strongly expressed in all day 3 embryos. The most representative dual co-expression of SARS-CoV–2-associated receptor and protease (60% of samples) during the embryonic genome activation stage (EGA) was ACE2-CTSL and BSG-CTSL. In blastocysts, ACE2, BSG, CTSL, CTSA and FURIN were detectable in the entire cohort at high expression level, and the prevalence of the different dual co-expression of SARS-CoV–2-associated proteases and receptors was optimal (100% of samples). Interestingly, only CTSL was detectable in all trophectoderm samples and a prevalence of 60% was found for the BSG-CTSL co-expression. ACE2, BSG, CTSL and CTSA were present at high expression level in CCs samples. In contrast, ACE2 and BSG expression was very low while CTSL and CTSA showed a high expression level in GCs.A prevalence of 100% was reported for ACE2-CTSL, ACE2-CTSA co-expression for both cell types. In addition, BSG-CTSL and BSG-CTSA co-expression were also present in all CCs against ∼70% in GCs samples. This data suggest a potential risks of SARS-CoV–2 infection either GC or early embryo development.
Limitations, reasons for caution
Analyses of Affymetrix microarray gene expression data were performed in non-COVID–19 patients. Whether the SARS-CoV–2 infection change the gene expression profile of SARS-CoV–2-associated receptors and proteases is under investigation.
Wider implications of the findings: Specimens from female genital tract may be considered as potential targets for SARS-CoV–2.
Trial registration number
Not applicable
Collapse
Affiliation(s)
- F Entezami
- American Hospital of Paris, IVF, Neuilly sur Seine, France
| | - D Haouzi
- Montpellier University, inserm U1203, Montpellier, France
| | - S Brouillet
- Montpellier University, inserm U1203, Montpellier, France
| | - F Barry
- Montpellier University, inserm U1203, Montpellier, France
| | - A Gala
- Montpellier University, inserm U1203, Montpellier, France
| | | | - S Hamamah
- Montpellier University, inserm U1203, Montpellier, France
| |
Collapse
|
24
|
Miralles A, Ducasse J, Brouillet S, Flouri T, Fujisawa T, Kapli P, Knowles LL, Kumari S, Stamatakis A, Sukumaran J, Lutteropp S, Vences M, Puillandre N. SPART: A versatile and standardized data exchange format for species partition information. Mol Ecol Resour 2021; 22:430-438. [PMID: 34288531 DOI: 10.1111/1755-0998.13470] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2021] [Revised: 06/25/2021] [Accepted: 07/12/2021] [Indexed: 11/28/2022]
Abstract
A wide range of data types can be used to delimit species and various computer-based tools dedicated to this task are now available. Although these formalized approaches have significantly contributed to increase the objectivity of species delimitation (SD) under different assumptions, they are not routinely used by alpha-taxonomists. One obvious shortcoming is the lack of interoperability among the various independently developed SD programs. Given the frequent incongruences between species partitions inferred by different SD approaches, researchers applying these methods often seek to compare these alternative species partitions to evaluate the robustness of the species boundaries. This procedure is excessively time consuming at present, and the lack of a standard format for species partitions is a major obstacle. Here, we propose a standardized format, SPART, to enable compatibility between different SD tools exporting or importing partitions. This format reports the partitions and describes, for each of them, the assignment of individuals to the "inferred species". The syntax also allows support values to be optionally reported, as well as original trees and the full command lines used in the respective SD analyses. Two variants of this format are proposed, overall using the same terminology but presenting the data either optimized for human readability (matricial SPART) or in a format in which each partition forms a separate block (SPART.XML). ABGD, DELINEATE, GMYC, PTP and TR2 have already been adapted to output SPART files and a new version of LIMES has been developed to import, export, merge and split them.
Collapse
Affiliation(s)
- Aurélien Miralles
- Institut de Systématique, Évolution, Biodiversité (ISYEB), Muséum national d'Histoire Naturelle, CNRS, Sorbonne Université, EPHE, Université des Antilles, Paris, France
| | | | - Sophie Brouillet
- Department of Genetics, Evolution and Environment, Centre for Life's Origins and Evolution, University College London, London, UK
| | - Tomas Flouri
- Department of Genetics, Evolution and Environment, Centre for Life's Origins and Evolution, University College London, London, UK
| | - Tomochika Fujisawa
- Center for Data Science Education and Research, Shiga University, Shiga, Japan
| | - Paschalia Kapli
- Department of Genetics, Evolution and Environment, Centre for Life's Origins and Evolution, University College London, London, UK
| | - L Lacey Knowles
- Department of Ecology and Evolution, University of Michigan, Ann Arbor, MI, USA
| | - Sangeeta Kumari
- Braunschweig University of Technology, Zoological Institute, Braunschweig, Germany
| | - Alexandros Stamatakis
- Computational Molecular Evolution Group, Heidelberg Institute for Theoretical Studies, Heidelberg, Germany.,Institute for Theoretical Informatics, Karlsruhe Institute of Technology, Karlsruhe, Germany
| | - Jeet Sukumaran
- Biology Department, LS 262, San Diego State University, San Diego, CA, USA
| | - Sarah Lutteropp
- Computational Molecular Evolution Group, Heidelberg Institute for Theoretical Studies, Heidelberg, Germany
| | - Miguel Vences
- Braunschweig University of Technology, Zoological Institute, Braunschweig, Germany
| | - Nicolas Puillandre
- Institut de Systématique, Évolution, Biodiversité (ISYEB), Muséum national d'Histoire Naturelle, CNRS, Sorbonne Université, EPHE, Université des Antilles, Paris, France
| |
Collapse
|
25
|
Haouzi D, Entezami F, Torre A, Innocenti C, Antoine Y, Mauries C, Vincens C, Bringer-Deutsch S, Gala A, Ferrieres-Hoa A, Ohl J, Gonzalez Marti B, Brouillet S, Hamamah S. Customized Frozen Embryo Transfer after Identification of the Receptivity Window with a Transcriptomic Approach Improves the Implantation and Live Birth Rates in Patients with Repeated Implantation Failure. Reprod Sci 2021; 28:69-78. [PMID: 32725589 PMCID: PMC7782404 DOI: 10.1007/s43032-020-00252-0] [Citation(s) in RCA: 20] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2020] [Revised: 06/04/2020] [Accepted: 06/30/2020] [Indexed: 01/10/2023]
Abstract
The aim of this prospective study was to evaluate outcome benefits expected in repeated implantation failure (RIF) patients (n = 217) after customized embryo transfer based upon identification of the receptivity window by transcriptomic approach using the Win-Test. In this test, the expression of 11 endometrial genes known to be predictive of endometrial receptivity is assessed by RT-PCR in biopsies collected during the implantation window (6-9 days after the spontaneous luteinizing hormone surge during natural cycles, 5-9 days after progesterone administration during hormone replacement therapy cycles). Then, patients underwent either customized embryo transfer (cET, n = 157 patients) according to the Win-Test results or embryo transfer according to the classical procedure (control group, n = 60). Pregnancy and live birth rates were compared in the two groups. The Win-Test showed that in 78.5% of women, the receptivity window lasted less than 48 h, although it could be shorter (< 24 h, 9.5%) or longer (> 48 h, 12%). This highlighted that only in 20% of patients with RIF the endometrium would have been receptive if the classical embryo transfer protocol was followed. In the other 80% of patients, the receptivity window was delayed by 1-3 days relative to the classical timing. This suggests that implantation failure could be linked to inadequate timing of embryo transfer. In agreement, both implantation (22.7% vs. 7.2%) and live birth rates per patient (31.8% vs. 8.3%) were significantly higher in the cET group than in the control group. cET on the basis of the Win-Test results could be proposed to improve pregnancy and live birth rates.ClinicalTrials.gov ID: NCT04192396; December 5, 2019, retrospectively registered.
Collapse
Affiliation(s)
- Delphine Haouzi
- Univ Montpellier, INSERM U1203, EmbryoPluripotency, Montpellier, France.
- IRMB, Univ Montpellier, INSERM, Montpellier, France.
- CHU Montpellier, ART/PGD Department, Arnaud de Villeneuve Hospital, Montpellier, France.
| | - Frida Entezami
- Univ Montpellier, INSERM U1203, EmbryoPluripotency, Montpellier, France
- ART Department, American Hospital of Paris, Neuilly-Sur-Seine, France
- Laboratoire Eylau-UNILABS-La Muette, Clinique de La Muette-Ramsay-Générale de Santé, Paris, France
| | - Antoine Torre
- Division of Child Health, Obstetrics & Gynaecology Department, University of Nottingham, Nottingham, UK
| | - Charlène Innocenti
- Univ Montpellier, INSERM U1203, EmbryoPluripotency, Montpellier, France
- IRMB, Univ Montpellier, INSERM, Montpellier, France
- CHU Montpellier, ART/PGD Department, Arnaud de Villeneuve Hospital, Montpellier, France
| | - Yannick Antoine
- Univ Montpellier, INSERM U1203, EmbryoPluripotency, Montpellier, France
- IRMB, Univ Montpellier, INSERM, Montpellier, France
| | - Charlotte Mauries
- CHU Montpellier, ART/PGD Department, Arnaud de Villeneuve Hospital, Montpellier, France
| | - Claire Vincens
- CHU Montpellier, ART/PGD Department, Arnaud de Villeneuve Hospital, Montpellier, France
| | | | - Anna Gala
- Univ Montpellier, INSERM U1203, EmbryoPluripotency, Montpellier, France
- CHU Montpellier, ART/PGD Department, Arnaud de Villeneuve Hospital, Montpellier, France
| | - Alice Ferrieres-Hoa
- Univ Montpellier, INSERM U1203, EmbryoPluripotency, Montpellier, France
- CHU Montpellier, ART/PGD Department, Arnaud de Villeneuve Hospital, Montpellier, France
| | - Jeanine Ohl
- Department of reproductive medicine, CMCO, Schiltigheim, France
| | - Beatriz Gonzalez Marti
- ART Department, American Hospital of Paris, Neuilly-Sur-Seine, France
- Laboratoire Eylau-UNILABS-La Muette, Clinique de La Muette-Ramsay-Générale de Santé, Paris, France
| | - Sophie Brouillet
- Univ Montpellier, INSERM U1203, EmbryoPluripotency, Montpellier, France
- IRMB, Univ Montpellier, INSERM, Montpellier, France
- CHU Montpellier, ART/PGD Department, Arnaud de Villeneuve Hospital, Montpellier, France
- Univ Grenoble-Alpes, INSERM U1036, Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Institut de Biosciences et Biotechnologies de Grenoble (BIG), Laboratoire Biologie du Cancer et de l'Infection (BCI), 38000, Grenoble, France
| | - Samir Hamamah
- Univ Montpellier, INSERM U1203, EmbryoPluripotency, Montpellier, France
- IRMB, Univ Montpellier, INSERM, Montpellier, France
- CHU Montpellier, ART/PGD Department, Arnaud de Villeneuve Hospital, Montpellier, France
| |
Collapse
|
26
|
Puillandre N, Brouillet S, Achaz G. ASAP: assemble species by automatic partitioning. Mol Ecol Resour 2020; 21:609-620. [PMID: 33058550 DOI: 10.1111/1755-0998.13281] [Citation(s) in RCA: 326] [Impact Index Per Article: 81.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2019] [Revised: 09/30/2020] [Accepted: 10/01/2020] [Indexed: 11/27/2022]
Abstract
Here, we describe Assemble Species by Automatic Partitioning (ASAP), a new method to build species partitions from single locus sequence alignments (i.e., barcode data sets). ASAP is efficient enough to split data sets as large 104 sequences into putative species in several minutes. Although grounded in evolutionary theory, ASAP is the implementation of a hierarchical clustering algorithm that only uses pairwise genetic distances, avoiding the computational burden of phylogenetic reconstruction. Importantly, ASAP proposes species partitions ranked by a new scoring system that uses no biological prior insight of intraspecific diversity. ASAP is a stand-alone program that can be used either through a graphical web-interface or that can be downloaded and compiled for local usage. We have assessed its power along with three others programs (ABGD, PTP and GMYC) on 10 real COI barcode data sets representing various degrees of challenge (from small and easy cases to large and complicated data sets). We also used Monte-Carlo simulations of a multispecies coalescent framework to assess the strengths and weaknesses of ASAP and the other programs. Through these analyses, we demonstrate that ASAP has the potential to become a major tool for taxonomists as it proposes rapidly in a full graphical exploratory interface relevant species hypothesis as a first step of the integrative taxonomy process.
Collapse
Affiliation(s)
- Nicolas Puillandre
- Institut Systématique Evolution Biodiversité (ISYEB), Muséum National d'Histoire Naturelle, CNRS, Sorbonne Université, EPHE, Université des Antilles, Paris, France
| | - Sophie Brouillet
- Institut Systématique Evolution Biodiversité (ISYEB), Muséum National d'Histoire Naturelle, CNRS, Sorbonne Université, EPHE, Université des Antilles, Paris, France
| | - Guillaume Achaz
- Institut Systématique Evolution Biodiversité (ISYEB), Muséum National d'Histoire Naturelle, CNRS, Sorbonne Université, EPHE, Université des Antilles, Paris, France.,SMILE Group, CIRB, UMR 7241, Collège de France, CNRS, INSERM, Paris, France.,Éco-anthropologie, Muséum National d'Histoire Naturelle, CNRS UMR 7206, Université de Paris, Paris, France
| |
Collapse
|
27
|
Alfaidy N, Brouillet S, Rajaraman G, Kalionis B, Hoffmann P, Barjat T, Benharouga M, Murthi P. The Emerging Role of the Prokineticins and Homeobox Genes in the Vascularization of the Placenta: Physiological and Pathological Aspects. Front Physiol 2020; 11:591850. [PMID: 33281622 PMCID: PMC7689260 DOI: 10.3389/fphys.2020.591850] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2020] [Accepted: 10/13/2020] [Indexed: 01/25/2023] Open
Abstract
Vasculogenesis and angiogenesis are key processes of placental development, which occur throughout pregnancy. Placental vasculogenesis occurs during the first trimester of pregnancy culminating in the formation of hemangioblasts from intra-villous stem cells. Placental angiogenesis occurs subsequently, forming new blood vessels from existing ones. Angiogenesis also takes place at the fetomaternal interface, allowing essential spiral arteriole remodeling to establish the fetomaternal circulation. Vasculogenesis and angiogenesis in animal models and in humans have been studied in a wide variety of in vitro, physiological and pathological conditions, with a focus on the pro- and anti-angiogenic factors that control these processes. Recent studies revealed roles for new families of proteins, including direct participants such as the prokineticin family, and regulators of these processes such as the homeobox genes. This review summarizes recent advances in understanding the molecular mechanisms of actions of these families of proteins. Over the past decade, evidence suggests increased production of placental anti-angiogenic factors, as well as angiogenic factors are associated with fetal growth restriction (FGR) and preeclampsia (PE): the most threatening pathologies of human pregnancy with systemic vascular dysfunction. This review also reports novel clinical strategies targeting members of these family of proteins to treat PE and its consequent effects on the maternal vascular system.
Collapse
Affiliation(s)
- Nadia Alfaidy
- Unité 1036, Institut National de la Santé et de la Recherche Médicale, Grenoble, France.,Department of Biology, University of Grenoble Alpes, Grenoble, France.,Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA), Biosciences and Biotechnology Institute of Grenoble, Grenoble, France
| | - Sophie Brouillet
- INSERM U1203, Department of Reproductive Biology, University of Montpellier, Montpellier, France
| | - Gayathri Rajaraman
- Faculty of Health and Biomedicine, First Year College, Victoria University, St. Albans, VIC, Australia
| | - Bill Kalionis
- Department of Maternal-Fetal Medicine, Obstetrics and Gynaecology, Pregnancy Research Centre, Royal Women's Hospital, The University of Melbourne, Parkville, VIC, Australia
| | - Pascale Hoffmann
- Unité 1036, Institut National de la Santé et de la Recherche Médicale, Grenoble, France.,Department of Biology, University of Grenoble Alpes, Grenoble, France.,Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA), Biosciences and Biotechnology Institute of Grenoble, Grenoble, France
| | - Tiphaine Barjat
- Unité 1059, Saint-Etienne Hospital, Institut National de la Santé et de la Recherche Médicale, Saint-Étienne, France
| | - Mohamed Benharouga
- Unité Mixte de Recherche 5249, Laboratoire de Chimie et Biologie des Métaux, Centre National de la Recherche Scientifique (CNRS), Grenoble, France
| | - Padma Murthi
- Department of Maternal-Fetal Medicine, Obstetrics and Gynaecology, Pregnancy Research Centre, Royal Women's Hospital, The University of Melbourne, Parkville, VIC, Australia.,Department of Pharmacology, The Ritchie Centre, Monash Biomedicine Discovery Institute, Hudson Institute of Medical Research, Monash University, Clayton, VIC, Australia
| |
Collapse
|
28
|
Brouillet S, Ferrieres-Hoa A, Fournier A, Martinez G, Bessonnat J, Gueniffey A, Gala A, Loup V, Hamamah S. Cryopreservation of Oocytes Retrieved from Ovarian Tissue to Optimize Fertility Preservation in Prepubertal Girls and Women. J Vis Exp 2020. [PMID: 33165323 DOI: 10.3791/61777] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022] Open
Abstract
Human ovarian tissue cryopreservation (OTC) is increasingly used worldwide to preserve female fertility in prepubertal girls and women at risk of premature ovarian insufficiency (POI) in the context of urgent gonadotoxic treatments or ovarian surgery. Fertility preservation is challenging because there is no consensus regarding patient management, preservation fertility strategies, or even technical laboratory protocols, which implies that each procedure must be adapted to the characteristics of the patient profile and its own risk-benefit ratio. During OTC, mature/immature oocytes can be aspirated directly from large/small antral follicles within ovarian tissue samples and/or be released into culture media from growing follicles during ovarian tissue dissection in prepubertal girls and women. In this manuscript, we present a protocol that combines ovarian tissue freezing with the cryopreservation of mature/immature oocytes retrieved from ovarian tissue samples, improving the reproductive potential of fertility preservation. Appropriate collection, handling, and storage of ovarian tissue and oocytes before, during, and after the cryopreservation will be described. The subsequent use and safety of cryopreserved/thawed ovarian tissue samples and oocytes will also be discussed, as well as the optimal timing for in vitro maturation of immature oocytes. We recommend the systematic use of this protocol in fertility preservation of prepubertal girls and women as it increases the whole reproductive potential of fertility preservation (i.e., oocyte vitrification in addition of OTC) and also improves the safety and use of fertility preservation (i.e., thawing of oocytes versus ovarian graft), maximizing the chance of successful childbirth for the patients at risk of POI.
Collapse
Affiliation(s)
- Sophie Brouillet
- Développement Embryonnaire Précoce Humain et Pluripotence, Univ Montpellier, INSERM 1203; Département de Biologie de la Reproduction, Biologie de la Reproduction/DPI et CECOS, CHU Montpellier, Univ Montpellier;
| | - Alice Ferrieres-Hoa
- Département de Biologie de la Reproduction, Biologie de la Reproduction/DPI et CECOS, CHU Montpellier, Univ Montpellier
| | - Alice Fournier
- Département de Biologie de la Reproduction, Biologie de la Reproduction/DPI et CECOS, CHU Montpellier, Univ Montpellier
| | | | | | | | - Anna Gala
- Département de Biologie de la Reproduction, Biologie de la Reproduction/DPI et CECOS, CHU Montpellier, Univ Montpellier
| | - Vanessa Loup
- Département de Biologie de la Reproduction, Biologie de la Reproduction/DPI et CECOS, CHU Montpellier, Univ Montpellier
| | - Samir Hamamah
- Développement Embryonnaire Précoce Humain et Pluripotence, Univ Montpellier, INSERM 1203; Département de Biologie de la Reproduction, Biologie de la Reproduction/DPI et CECOS, CHU Montpellier, Univ Montpellier
| |
Collapse
|
29
|
Alfaidy N, Baron C, Antoine Y, Reynaud D, Traboulsi W, Gueniffey A, Lamotte A, Melloul E, Dunand C, Villaret L, Bessonnat J, Mauroy C, Boueihl T, Coutton C, Martinez G, Hamamah S, Hoffmann P, Hennebicq S, Brouillet S. Prokineticin 1 is a new biomarker of human oocyte competence: expression and hormonal regulation throughout late folliculogenesis. Biol Reprod 2020; 101:832-841. [PMID: 31276578 DOI: 10.1093/biolre/ioz114] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2019] [Revised: 04/08/2019] [Accepted: 07/04/2019] [Indexed: 12/19/2022] Open
Abstract
CONTEXT Prokineticin 1 (PROK1) quantification in global follicular fluid (FF) has been recently reported as a predictive biomarker of in vitro fertilization (IVF) outcome. It is now necessary to evaluate its clinical usefulness in individual follicles. OBJECTIVES To evaluate the clinical value of PROK1 secretion in individual FF to predict oocyte competence. To determine the impact of follicular size, oocyte maturity, and gonadotropin treatments on PROK1 secretion. DESIGN AND SETTING Prospective cohort study from May 2015 to May 2017 at the University Hospital of Grenoble. PATIENTS A total of 69 infertile couples underwent IVF. INTERVENTION(S) Collection of 298 individual FF from 44 women undergoing IVF; 52 individual cumulus cell (CC) samples and 15 CC primary cultures from 25 women undergoing IVF-intracytoplasmic sperm injection (ICSI). MAIN OUTCOME MEASURE(S) Oocyte competence was defined as the ability to sustain embryo development to the blastocyst stage. Follicular size was measured by 2D-sonography. PROK1 concentration was quantified by ELISA assay. RESULTS PROK1 concentration was correlated to follicular size (r = 0.85, P = 2.2 × 10-16). Normalized PROK1 concentration in FF was predictive of subsequent oocyte competence (AUROC curve = 0.76 [95% CI, 0.69-0.83]; P = 1.7 × 10-9), irrespectively of day-2 embryo morphokinetic parameters. The expression and secretion of PROK1 were increased in FF and CC of mature oocytes (P < 0.01). Follicle Stimulating Hormone and hCG up-regulated PROK1 secretion in CC primary cultures (P < 0.01; P < 0.05), probably through the cAMP pathway (P < 0.01). CONCLUSIONS PROK1 quantification in individual FF could constitute a new predictive biomarker of oocyte competence in addition with embryo morphokinetic parameters. TRIAL REGISTRATION NUMBER none.
Collapse
Affiliation(s)
- Nadia Alfaidy
- Université Grenoble-Alpes, Inserm, Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Institut de Biosciences et Biotechnologies de Grenoble (BIG), Laboratoire Biologie du Cancer et de l'Infection (BCI), 38000, Grenoble, France
| | - Chloé Baron
- Université Grenoble-Alpes, Inserm, Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Institut de Biosciences et Biotechnologies de Grenoble (BIG), Laboratoire Biologie du Cancer et de l'Infection (BCI), 38000, Grenoble, France
- Centre Hospitalier Universitaire de Grenoble, Hôpital Couple-Enfant, Centre Clinique et Biologique d'Assistance Médicale à la Procréation- Centre d'étude et de conservation des œufs et du sperme humains (CECOS), 38700, La Tronche, France
- INSERM U1203, Equipe "Développement Embryonnaire Précoce Humain et Pluripotence", Institut de Médecine Régénératrice et de Biothérapie, Hôpital Saint-Eloi, Montpellier 34295, France
| | - Yannick Antoine
- INSERM U1203, Equipe "Développement Embryonnaire Précoce Humain et Pluripotence", Institut de Médecine Régénératrice et de Biothérapie, Hôpital Saint-Eloi, Montpellier 34295, France
| | - Déborah Reynaud
- Université Grenoble-Alpes, Inserm, Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Institut de Biosciences et Biotechnologies de Grenoble (BIG), Laboratoire Biologie du Cancer et de l'Infection (BCI), 38000, Grenoble, France
| | - Wael Traboulsi
- Université Grenoble-Alpes, Inserm, Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Institut de Biosciences et Biotechnologies de Grenoble (BIG), Laboratoire Biologie du Cancer et de l'Infection (BCI), 38000, Grenoble, France
| | - Aurore Gueniffey
- Centre Hospitalier Universitaire de Grenoble, Hôpital Couple-Enfant, Centre Clinique et Biologique d'Assistance Médicale à la Procréation- Centre d'étude et de conservation des œufs et du sperme humains (CECOS), 38700, La Tronche, France
| | - Anna Lamotte
- Centre Hospitalier Universitaire de Grenoble, Hôpital Couple-Enfant, Centre Clinique et Biologique d'Assistance Médicale à la Procréation- Centre d'étude et de conservation des œufs et du sperme humains (CECOS), 38700, La Tronche, France
| | - Eve Melloul
- Centre Hospitalier Universitaire de Grenoble, Hôpital Couple-Enfant, Centre Clinique et Biologique d'Assistance Médicale à la Procréation- Centre d'étude et de conservation des œufs et du sperme humains (CECOS), 38700, La Tronche, France
| | - Camille Dunand
- Centre Hospitalier Universitaire de Grenoble, Hôpital Couple-Enfant, Centre Clinique et Biologique d'Assistance Médicale à la Procréation- Centre d'étude et de conservation des œufs et du sperme humains (CECOS), 38700, La Tronche, France
| | - Laure Villaret
- Centre Hospitalier Universitaire de Grenoble, Hôpital Couple-Enfant, Centre Clinique et Biologique d'Assistance Médicale à la Procréation- Centre d'étude et de conservation des œufs et du sperme humains (CECOS), 38700, La Tronche, France
| | - Julien Bessonnat
- Centre Hospitalier Universitaire de Grenoble, Hôpital Couple-Enfant, Centre Clinique et Biologique d'Assistance Médicale à la Procréation- Centre d'étude et de conservation des œufs et du sperme humains (CECOS), 38700, La Tronche, France
| | - Charlotte Mauroy
- Centre Hospitalier Universitaire de Grenoble, Hôpital Couple-Enfant, Centre Clinique et Biologique d'Assistance Médicale à la Procréation- Centre d'étude et de conservation des œufs et du sperme humains (CECOS), 38700, La Tronche, France
| | - Thomas Boueihl
- Centre Hospitalier Universitaire de Grenoble, Hôpital Couple-Enfant, Centre Clinique et Biologique d'Assistance Médicale à la Procréation- Centre d'étude et de conservation des œufs et du sperme humains (CECOS), 38700, La Tronche, France
| | - Charles Coutton
- Université Grenoble-Alpes, Inserm, Institute for Advanced Biosciences (IAB), équipe Génétique Epigénétique et Thérapie de l'Infertilité (GETI), 38000, Grenoble, France
- Centre Hospitalier Universitaire de Grenoble, Hôpital Couple Enfant, Département de Génétique et Procréation, Laboratoire de Génétique Chromosomique, 38700, La Tronche, France
| | - Guillaume Martinez
- Centre Hospitalier Universitaire de Grenoble, Hôpital Couple Enfant, Département de Génétique et Procréation, Laboratoire de Génétique Chromosomique, 38700, La Tronche, France
| | - Samir Hamamah
- INSERM U1203, Equipe "Développement Embryonnaire Précoce Humain et Pluripotence", Institut de Médecine Régénératrice et de Biothérapie, Hôpital Saint-Eloi, Montpellier 34295, France
- CHU Montpellier, ART/PGD Division, Hôpital Arnaud de Villeneuve, Montpellier 34295, France
| | - Pascale Hoffmann
- Université Grenoble-Alpes, Inserm, Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Institut de Biosciences et Biotechnologies de Grenoble (BIG), Laboratoire Biologie du Cancer et de l'Infection (BCI), 38000, Grenoble, France
- Centre Hospitalier Universitaire de Grenoble, Hôpital Couple-Enfant, Centre Clinique et Biologique d'Assistance Médicale à la Procréation- Centre d'étude et de conservation des œufs et du sperme humains (CECOS), 38700, La Tronche, France
| | - Sylviane Hennebicq
- Centre Hospitalier Universitaire de Grenoble, Hôpital Couple-Enfant, Centre Clinique et Biologique d'Assistance Médicale à la Procréation- Centre d'étude et de conservation des œufs et du sperme humains (CECOS), 38700, La Tronche, France
- Université Grenoble-Alpes, Inserm, Institute for Advanced Biosciences (IAB), équipe Génétique Epigénétique et Thérapie de l'Infertilité (GETI), 38000, Grenoble, France
| | - Sophie Brouillet
- Université Grenoble-Alpes, Inserm, Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Institut de Biosciences et Biotechnologies de Grenoble (BIG), Laboratoire Biologie du Cancer et de l'Infection (BCI), 38000, Grenoble, France
- Centre Hospitalier Universitaire de Grenoble, Hôpital Couple-Enfant, Centre Clinique et Biologique d'Assistance Médicale à la Procréation- Centre d'étude et de conservation des œufs et du sperme humains (CECOS), 38700, La Tronche, France
- INSERM U1203, Equipe "Développement Embryonnaire Précoce Humain et Pluripotence", Institut de Médecine Régénératrice et de Biothérapie, Hôpital Saint-Eloi, Montpellier 34295, France
| |
Collapse
|
30
|
Haouzi D, Entezami F, Mauries C, Ferrieres-Hoa A, Gala A, Vintejoux E, Brunet C, Vincens C, Bringer-Deutsch S, Brouillet S, Hamamah S. IMPROVEMENT OF PREGNANCY OUTCOME BY TARGETING A CUSTOMIZED TIMING OF FROZEN EMBRYO TRANSFER IN PATIENTS FOR DONOR EGG RECIPIENTS. Fertil Steril 2020. [DOI: 10.1016/j.fertnstert.2020.08.906] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
31
|
Baron C, Haouzi D, Entezami F, Brouillet S, Hamamah S. CIRCULATING MIRNAS AS A NON-INVASIVE DIAGNOSTIC TOOL TO PREDICT IMPLANTATION FAILURE. Fertil Steril 2020. [DOI: 10.1016/j.fertnstert.2020.08.1023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
32
|
Entezami F, Haouzi D, Ferrieres-Hoa A, Brouillet S, Vincens C, Bringer-Deutsch S, Vintejoux E, Hamamah S. REPEATED IMPLANTATION FAILURE AND WINDOW OF IMPLANTATION TESTING: A WINNING DUET TO IMPROVE LIVE BIRTH RATE. Fertil Steril 2020. [DOI: 10.1016/j.fertnstert.2020.08.827] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
33
|
Brouillet S, Andreeva A, Gala A, Ferrieres-Hoa A, Anav M, Fournier A, Loup V, Ranisavljevic N, Hamamah S. ULTRA LOW OXYGEN EXPOSURE DURING EXTENDED CULTURE OF HUMAN EMBRYO SIGNIFICANTLY IMPROVES USABLE BLASTULATION AND CUMULATIVE LIVE BIRTH RATES IN FERTILIZATION. Fertil Steril 2020. [DOI: 10.1016/j.fertnstert.2020.08.145] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
34
|
Drissennek L, Baron C, Brouillet S, Entezami F, Hamamah S, Haouzi D. Endometrial miRNome profile according to the receptivity status and implantation failure. HUM FERTIL 2020; 25:356-368. [DOI: 10.1080/14647273.2020.1807065] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Affiliation(s)
- Loubna Drissennek
- Univ Montpellier, INSERM U1203, EmbryoPluripotency, Montpellier, France
- IRMB, Univ Montpellier, INSERM, Montpellier, France
| | - Chloé Baron
- Univ Montpellier, INSERM U1203, EmbryoPluripotency, Montpellier, France
- IRMB, Univ Montpellier, INSERM, Montpellier, France
| | - Sophie Brouillet
- Univ Montpellier, INSERM U1203, EmbryoPluripotency, Montpellier, France
- IRMB, Univ Montpellier, INSERM, Montpellier, France
- CHU Montpellier, ART/PDG department, Arnaud de Villeneuve Hospital, Montpellier, Montpellier, France
- Univ Grenoble-Alpes, INSERM 1036, Institut de Biosciences et Biotechnologies de Grenoble (BIG), Laboratoire Biologie du Cancer et de l’Infection (BCI), Grenoble, France
| | - Frida Entezami
- Univ Montpellier, INSERM U1203, EmbryoPluripotency, Montpellier, France
- American Hospital of Paris, IVF department, Neuilly-Sur-Seine, France
| | - Samir Hamamah
- Univ Montpellier, INSERM U1203, EmbryoPluripotency, Montpellier, France
- IRMB, Univ Montpellier, INSERM, Montpellier, France
- CHU Montpellier, ART/PDG department, Arnaud de Villeneuve Hospital, Montpellier, Montpellier, France
| | - Delphine Haouzi
- Univ Montpellier, INSERM U1203, EmbryoPluripotency, Montpellier, France
- IRMB, Univ Montpellier, INSERM, Montpellier, France
- CHU Montpellier, ART/PDG department, Arnaud de Villeneuve Hospital, Montpellier, Montpellier, France
| |
Collapse
|
35
|
Mauries C, Ranisavljevic N, Gallet R, Fournier A, Gala A, Ferrières-Hoa A, Brouillet S, Hamamah S. [Assessment of genital microbiota: An emerging approach in assisted reproductive techniques]. ACTA ACUST UNITED AC 2020; 49:185-192. [PMID: 32758671 DOI: 10.1016/j.gofs.2020.07.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2020] [Indexed: 10/23/2022]
Abstract
The genital microbiota actively participates in women's reproductive health. Indeed, a genital dysbiosis (microbial imbalance associated with adverse effects on host health) can lead to vaginal infections (such as mycoses or bacterial vaginosis). Recent data reported that genital dysbiosis (e.g. vaginal or endometrial) was associated with fewer chances of live births in assisted reproductive technologies (ART), via decreased pregnancy rates and an increased risk of miscarriages. The presence or diversity of certain bacterial strains (in particular Gardenellavaginalis, Proteobacteria, Lactobacillusjensenii, Lactobacilluscrispatus or Atopobiumvaginae) within the genital microbiota seem to be associated with the outcomes of ART cycles, suggesting new approaches to improve ART results. In this review, we aim at presenting the state of art on the association between the female genital microbiota and ART success. The diagnostic and therapeutic approaches (i.e. probiotics, antibiotic therapy and transplantation of vaginal microbiota) in the management of patients with altered microbiota will also be discussed. The confirmation of these data in the coming years could significantly improve the management of infertile patients in ART with a more personalized approach partially based on the female genital microbiotic profile.
Collapse
Affiliation(s)
- C Mauries
- Département de biologie de la reproduction, CHU de Montpellier, université de Montpellier, 34000 Montpellier, France
| | - N Ranisavljevic
- Département de médecine de la reproduction, CHU de Montpellier, université de Montpellier, 34000 Montpellier, France
| | - R Gallet
- Inserm 1203, développement embryonnaire précoce humain et pluripotence, université de Montpellier, 34000 Montpellier, France
| | - A Fournier
- Département de biologie de la reproduction, CHU de Montpellier, université de Montpellier, 34000 Montpellier, France; Inserm 1203, développement embryonnaire précoce humain et pluripotence, université de Montpellier, 34000 Montpellier, France
| | - A Gala
- Département de biologie de la reproduction, CHU de Montpellier, université de Montpellier, 34000 Montpellier, France; Inserm 1203, développement embryonnaire précoce humain et pluripotence, université de Montpellier, 34000 Montpellier, France
| | - A Ferrières-Hoa
- Département de biologie de la reproduction, CHU de Montpellier, université de Montpellier, 34000 Montpellier, France; Inserm 1203, développement embryonnaire précoce humain et pluripotence, université de Montpellier, 34000 Montpellier, France
| | - S Brouillet
- Département de biologie de la reproduction, CHU de Montpellier, université de Montpellier, 34000 Montpellier, France; Inserm 1203, développement embryonnaire précoce humain et pluripotence, université de Montpellier, 34000 Montpellier, France; Centre clinique et biologique d'assistance médicale à la procréation, centre d'étude et de conservation des œufs et du sperme humains (CECOS), centre hospitalier universitaire de Grenoble, hôpital Couple-enfant, 38700 La Tronche, France.
| | - S Hamamah
- Département de biologie de la reproduction, CHU de Montpellier, université de Montpellier, 34000 Montpellier, France; Inserm 1203, développement embryonnaire précoce humain et pluripotence, université de Montpellier, 34000 Montpellier, France.
| |
Collapse
|
36
|
Baron C, Haouzi D, Gala A, Ferrieres-Hoa A, Vintejoux E, Brouillet S, Hamamah S. [Endometrial receptivity in assisted reproductive techniques: An aspect to investigate in embryo implantation failure]. ACTA ACUST UNITED AC 2020; 49:128-136. [PMID: 32721539 DOI: 10.1016/j.gofs.2020.07.003] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2020] [Indexed: 10/23/2022]
Abstract
Infertility affects between 8 and 12% of reproductive-age couples worldwide. Despite improvements in assisted reproductive techniques (ART), live birth rates are still limited. In clinical practice, imaging and microscopy are currently widely used, but their diagnostic effectiveness remains limited. In research, the emergence of innovative techniques named OMICS would improve the identification of the implantation window, while progressing in the understanding of the pathophysiological mechanisms involved in embryo implantation failures. To date, transcriptomic analysis seems to be the most promising approach in clinical research. The objective of this review is to present the results obtained with the different approaches available in clinical practice and in research to assess endometrial receptivity in patients undergoing ART.
Collapse
Affiliation(s)
- C Baron
- Inserm U1203, développement embryonnaire précoce humain et pluripotence, université Montpellier, Montpellier, France
| | - D Haouzi
- Inserm U1203, développement embryonnaire précoce humain et pluripotence, université Montpellier, Montpellier, France
| | - A Gala
- Département de biologie de la reproduction, biologie de la reproduction et diagnostic pre-implantatoire, université Montpellier, CHU Montpellier, Montpellier, France
| | - A Ferrieres-Hoa
- Département de biologie de la reproduction, biologie de la reproduction et diagnostic pre-implantatoire, université Montpellier, CHU Montpellier, Montpellier, France
| | - E Vintejoux
- Département de médecine de la reproduction, CHU de Montpellier, 34000 Montpellier, France
| | - S Brouillet
- Inserm U1203, développement embryonnaire précoce humain et pluripotence, université Montpellier, Montpellier, France; Département de biologie de la reproduction, biologie de la reproduction et diagnostic pre-implantatoire, université Montpellier, CHU Montpellier, Montpellier, France; Inserm 1036, laboratoire biologie du cancer et de l'infection (BCI), Commissariat à l'énergie atomique et aux énergies alternatives (CEA), institut de biosciences et biotechnologies de Grenoble (BIG), université Grenoble-Alpes, 38000 Grenoble, France; Centre clinique et biologique d'assistance médicale à la procréation - centre d'étude et de conservation des œufs et du sperme humains (CECOS), hôpital Couple-Enfant, centre hospitalier universitaire de Grenoble, La Tronche, France.
| | - S Hamamah
- Inserm U1203, développement embryonnaire précoce humain et pluripotence, université Montpellier, Montpellier, France; Département de biologie de la reproduction, biologie de la reproduction et diagnostic pre-implantatoire, université Montpellier, CHU Montpellier, Montpellier, France.
| |
Collapse
|
37
|
Bouzoubaa SM, Benlahfid M, Sidqui M, Aboussaouira T, Rifki C, Brouillet S, Traboulsi W, Alfaidy N, Benharouga M. Vascular endothelial growth factor (VEGF) and Endocrine gland-VEGF (EG-VEGF) are down regulated in head and neck cancer. Clin Otolaryngol 2020; 45:788-795. [PMID: 32516473 DOI: 10.1111/coa.13595] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2019] [Revised: 04/23/2020] [Accepted: 05/25/2020] [Indexed: 11/29/2022]
Abstract
OBJECTIVE To characterise the role of VEGF, EG-VEGF and its receptors in the development and progression of HNC. DESIGN Human serum and tissues samples were collected from healthy, epulis and HNC patients and used for ELISA assays and immunohistochemistry studies, respectively. SETTING Ibn Rochd Hospital of Casablanca (Morocco), INSERM and University of Grenoble Alpes (France). PARTICIPANTS We used serum from 64 patients with head and neck cancers and from 71 controls without general pathology. Tissues samples were collected from seven patients with OSCC and from seven patients with Epulis. MAIN OUTCOME MEASURES We compared circulating VEGF and EG-VEGF in normal and HNC patients and determined the expression, localisation and quantification of VEGF, EG-VEGF and its receptors; PROKR1 and PROKR2 as well as Ki67, CD31 and CD34 in OSCC and Epulis patients. RESULTS Both EG-VEGF and VEGF circulating levels were significantly decreased in the HNC (P < .01). OSCC patients expressed less EG-VEGF and VEGF proteins, higher PROKR1 and PROKR2 with no change in CD31 and CD34 levels. A significant increase in Ki67 was observed in OSCC. CONCLUSIONS We demonstrated that circulating VEGF and EG-VEGF are downregulated in HNC patients and in OSCC tissue. EG-VEGF receptors were increased in OSCC, along with a stabilisation of two key markers of angiogenesis. These findings strongly suggest that downregulation of angiogenesis in HNC might explain its moderate metastatic feature.
Collapse
Affiliation(s)
- Si Mohamed Bouzoubaa
- Faculté de Médecine et de Pharmacie de Casablanca, Université Hassan II, Centre Hospitalier Universitaire (CHU) Ibn Rochd de Casablanca, Casablanca, Maroc
| | - Mohammed Benlahfid
- Faculté de Médecine et de Pharmacie de Casablanca, Université Hassan II, Centre Hospitalier Universitaire (CHU) Ibn Rochd de Casablanca, Casablanca, Maroc
| | - Mustapha Sidqui
- Faculté de Médecine et de Pharmacie de Casablanca, Université Hassan II, Centre Hospitalier Universitaire (CHU) Ibn Rochd de Casablanca, Casablanca, Maroc
| | - Touria Aboussaouira
- Faculté de Médecine et de Pharmacie de Casablanca, Université Hassan II, Centre Hospitalier Universitaire (CHU) Ibn Rochd de Casablanca, Casablanca, Maroc
| | - Chouaib Rifki
- Faculté de Médecine et de Pharmacie de Casablanca, Université Hassan II, Centre Hospitalier Universitaire (CHU) Ibn Rochd de Casablanca, Casablanca, Maroc
| | - Sophie Brouillet
- Institut National de la Santé et de la Recherche Médicale (INSERM), Grenoble, France.,University Grenoble-Alpes (UGA), Grenoble, France.,Hôpital Couple-Enfant, Centre Clinique et Biologique d'Assistance Médicale à la Procréation-CECOS, Centre Hospitalier Universitaire de Grenoble, La Tronche, France
| | - Wael Traboulsi
- Institut National de la Santé et de la Recherche Médicale (INSERM), Grenoble, France.,University Grenoble-Alpes (UGA), Grenoble, France.,Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA), Biosciences and Biotechnology Institute (BIG) of Grenoble, Grenoble, France
| | - Nadia Alfaidy
- Institut National de la Santé et de la Recherche Médicale (INSERM), Grenoble, France.,University Grenoble-Alpes (UGA), Grenoble, France.,Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA), Biosciences and Biotechnology Institute (BIG) of Grenoble, Grenoble, France
| | - Mohamed Benharouga
- University Grenoble-Alpes (UGA), Grenoble, France.,Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA), Biosciences and Biotechnology Institute (BIG) of Grenoble, Grenoble, France.,Centre National de la Recherche Scientifique (CNRS), UMR 5249, Laboratoire de Chimie et Biologie des Métaux (LCBM), Grenoble, France
| |
Collapse
|
38
|
Martinez G, Lacoste R, Dumasy M, Garbit S, Brouillet S, Coutton C, Arnoult C, Druelle F, Molina-Vila P. Deslorelin acetate implant induces transient sterility and behavior changes in male olive baboon (Papio anubis): A case study. J Med Primatol 2020; 49:344-348. [PMID: 32524631 DOI: 10.1111/jmp.12479] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2020] [Revised: 03/31/2020] [Accepted: 05/21/2020] [Indexed: 11/29/2022]
Abstract
This case study evaluates the effects of a 4.7 mg deslorelin acetate implant on one male olive baboon (Papio anubis). Implantation induces transient azoospermia after which the subject was able to conceive again. Behavior was also impacted with a decrease in our proxies of aggressiveness and sexual arousal.
Collapse
Affiliation(s)
- Guillaume Martinez
- Centre Hospitalier Universitaire de Grenoble, Hôpital Couple-Enfant, UM de Génétique Chromosomique, Grenoble, France.,Genetic Epigenetic and Therapies of Infertility, Institute for Advanced Biosciences INSERM U1209, UMR5309, CNRS, Grenoble, France
| | | | - Marie Dumasy
- Station de Primatologie, UPS846, CNRS, Rousset, France
| | | | - Sophie Brouillet
- Centre Clinique et Biologique d'Assistance Médicale à la Procréation-CECOS, Hôpital Couple-Enfant, Centre Hospitalier Universitaire de Grenoble, La Tronche, France
| | - Charles Coutton
- Centre Hospitalier Universitaire de Grenoble, Hôpital Couple-Enfant, UM de Génétique Chromosomique, Grenoble, France.,Genetic Epigenetic and Therapies of Infertility, Institute for Advanced Biosciences INSERM U1209, UMR5309, CNRS, Grenoble, France
| | - Christophe Arnoult
- Genetic Epigenetic and Therapies of Infertility, Institute for Advanced Biosciences INSERM U1209, UMR5309, CNRS, Grenoble, France
| | - François Druelle
- Station de Primatologie, UPS846, CNRS, Rousset, France.,HNHP, UMR 7194, MNHN, Paris, France
| | | |
Collapse
|
39
|
Brouillet S, Boursier G, Anav M, Du Boulet De La Boissière B, Gala A, Ferrieres-Hoa A, Touitou I, Hamamah S. C-reactive protein and ART outcomes: a systematic review. Hum Reprod Update 2020; 26:753-773. [DOI: 10.1093/humupd/dmaa012] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2019] [Revised: 01/17/2020] [Indexed: 12/23/2022] Open
Abstract
Abstract
BACKGROUND
A dynamic balance between pro- and anti-inflammatory factors contributes to regulating human female reproduction. Chronic low-grade inflammation has been detected in several female reproductive conditions, from anovulation to embryo implantation failure. C-reactive protein (CRP) is a reliable marker of inflammation that is extensively used in clinical practice. Recent studies quantified CRP in the serum of infertile women undergoing ART and suggested its potential for the prediction of ART reproductive outcomes.
OBJECTIVE AND RATIONALE
The first objective of this systematic review of the available literature was to evaluate the association between pre-implantation circulating CRP concentration and pregnancy rates in women undergoing ART. The second objective was to describe serum CRP concentration changes after early embryo implantation. The changes in circulating CRP throughout the ART cycle, clinical implications of CRP quantification for the management of women undergoing ART, and future therapeutic options will also be discussed.
SEARCH METHODS
The MEDLINE database was systematically searched from inception to March 2019 using the following key words: (C-reactive protein) AND (assisted reproductive techniques OR ovulation induction OR insemination OR in vitro fertilization). Only articles in English were considered. Studies were selected based on title and abstract. The full text of potentially relevant articles was retrieved and assessed for inclusion by two reviewers (S.B. and S.H.). The protocol was registered in the International prospective register of systematic reviews (PROSPERO; registration number: CRD148687).
OUTCOMES
In total, 10 studies were included in this systematic review. Most of these studies reported lower circulating CRP values before the window of implantation and higher circulating CRP values during the peri-implantation period in women with successful ART outcome (biochemical or clinical pregnancy) compared to women without a successful outcome. Several lifestyle factors and/or drugs that reduce the concentration of circulating CRP significantly improve ART outcomes. Subgroup analyses according to female BMI and baseline circulating CRP concentration are highly recommended in future analyses.
WIDER IMPLICATIONS
These findings highlight a possible detrimental impact of preconception high circulating CRP concentration on ART outcomes. However, the biochemical or clinical pregnancy rate endpoints used in the studies examined here are insufficient (there were no data on live birth outcome), and the impact of major variables that can influence CRP and/or ART, for example maternal age, BMI, number of transferred embryos, and use of anti-inflammatory drugs, were not considered in the analyses. CRP quantification may be a potential marker of ART outcome, but its predictive value still needs to be investigated in large prospective studies. In future, the quantification of circulating CRP before starting ART could help to identify patients with a poor ART prognosis, leading to ART cycle cancellation or to preconception treatment to minimize the medical risks and costs.
Collapse
Affiliation(s)
- Sophie Brouillet
- Université Grenoble-Alpes, Inserm 1036, Commissariat à l'Énergie Atomique et aux Énergies Alternatives (CEA), Institut de Biosciences et Biotechnologies de Grenoble (BIG), Laboratoire Biologie du Cancer et de l’Infection (BCI), 38000 Grenoble, France
- Centre Hospitalier Universitaire de Grenoble, Hôpital Couple-Enfant, Centre Clinique et Biologique d’Assistance Médicale à la Procréation-Centre d'Étude et de Conservation des Oeufs et du Sperme Humains (CECOS), La Tronche, France
- Univ Montpellier, Développement Embryonnaire Précoce Humain et Pluripotence, INSERM 1203, Montpellier, France
- CHU Montpellier, Univ Montpellier, Département de Biologie de la Reproduction, Biologie de la Reproduction et Diagnostic Pre-Implantatoire, Montpellier, France
| | - Guilaine Boursier
- CHU Montpellier, Univ Montpellier, Département de Génétique Médicale, Maladies Rares et Médecine Personnalisée, Génétique des Maladies Rares et Autoinflammatoires, Montpellier, France
| | - Margaux Anav
- CHU Montpellier, Univ Montpellier, Département de Biologie de la Reproduction, Biologie de la Reproduction et Diagnostic Pre-Implantatoire, Montpellier, France
| | - Bertille Du Boulet De La Boissière
- CHU Montpellier, Univ Montpellier, Département de Biologie de la Reproduction, Biologie de la Reproduction et Diagnostic Pre-Implantatoire, Montpellier, France
| | - Anna Gala
- CHU Montpellier, Univ Montpellier, Département de Biologie de la Reproduction, Biologie de la Reproduction et Diagnostic Pre-Implantatoire, Montpellier, France
| | - Alice Ferrieres-Hoa
- CHU Montpellier, Univ Montpellier, Département de Biologie de la Reproduction, Biologie de la Reproduction et Diagnostic Pre-Implantatoire, Montpellier, France
| | - Isabelle Touitou
- CHU Montpellier, Univ Montpellier, Département de Génétique Médicale, Maladies Rares et Médecine Personnalisée, Génétique des Maladies Rares et Autoinflammatoires, Montpellier, France
- Cellules Souches, Plasticité Cellulaire, Médecine Régénératrice et Immunothérapies, INSERM, Univ de Montpellier, Montpellier, France
| | - Samir Hamamah
- Univ Montpellier, Développement Embryonnaire Précoce Humain et Pluripotence, INSERM 1203, Montpellier, France
- CHU Montpellier, Univ Montpellier, Département de Biologie de la Reproduction, Biologie de la Reproduction et Diagnostic Pre-Implantatoire, Montpellier, France
| |
Collapse
|
40
|
Brouillet S, Martinez G, Coutton C, Hamamah S. Is cell-free DNA in spent embryo culture medium an alternative to embryo biopsy for preimplantation genetic testing? A systematic review. Reprod Biomed Online 2020; 40:779-796. [PMID: 32417199 DOI: 10.1016/j.rbmo.2020.02.002] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2019] [Revised: 01/29/2020] [Accepted: 02/02/2020] [Indexed: 12/17/2022]
Abstract
Preimplantation genetic testing (PGT) is increasingly used worldwide. It currently entails the use of invasive techniques, i.e. polar body, blastomere, trophectoderm biopsy or blastocentesis, to obtain embryonic DNA, with major technical limitations and ethical issues. Evidence suggests that invasive PGT can lead to genetic misdiagnosis in the case of embryo mosaicism, and, consequently, to the selection of affected embryos for implantation or to the destruction of healthy embryos. Recently, spent culture medium (SCM) has been proposed as an alternative source of embryonic DNA. An increasing number of studies have reported the detection of cell-free DNA in SCM and highlighted the diagnostic potential of non-invasive SCM-based PGT for assessing the genetic status of preimplantation human embryos obtained by IVF. The reliability of this approach for clinical applications, however, needs to be determined. In this systematic review, published evidence on non-invasive SCM-based PGT is presented, and its current benefits and limitations compared with invasive PGT. Then, ways of optimizing and standardizing procedures for non-invasive SCM-based PGT to prevent technical biases and to improve performance in future studies are discussed. Finally, clinical perspectives of non-invasive PGT are presented and its future applications in reproductive medicine highlighted.
Collapse
Affiliation(s)
- Sophie Brouillet
- Université Grenoble-Alpes, Inserm 1036, Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Institut de Biosciences et Biotechnologies de Grenoble (BIG), Laboratoire Biologie du Cancer et de l'Infection (BCI), Grenoble 38000, France; Centre Hospitalier Universitaire de Grenoble, Hôpital Couple-Enfant, Centre Clinique et Biologique d'Assistance Médicale à la Procréation- Centre d'étude et de conservation des œufs et du sperme humains (CECOS), La Tronche 38700, France; INSERM U1203, Equipe "Développement Embryonnaire Précoce Humain et Pluripotence", Institut de Médecine Régénératrice et de Biothérapie, Hôpital Saint-Eloi, Montpellier 34295, France
| | - Guillaume Martinez
- Université Grenoble-Alpes, Inserm, Institute for Advanced Biosciences (IAB), équipe Génétique Epigénétique et Thérapie de l'Infertilité (GETI), Grenoble 38000, France; Centre Hospitalier Universitaire de Grenoble, Hôpital Couple Enfant, Département de Génétique et Procréation, Laboratoire de Génétique Chromosomique, La Tronche 38700, France
| | - Charles Coutton
- Université Grenoble-Alpes, Inserm, Institute for Advanced Biosciences (IAB), équipe Génétique Epigénétique et Thérapie de l'Infertilité (GETI), Grenoble 38000, France; Centre Hospitalier Universitaire de Grenoble, Hôpital Couple Enfant, Département de Génétique et Procréation, Laboratoire de Génétique Chromosomique, La Tronche 38700, France
| | - Samir Hamamah
- INSERM U1203, Equipe "Développement Embryonnaire Précoce Humain et Pluripotence", Institut de Médecine Régénératrice et de Biothérapie, Hôpital Saint-Eloi, Montpellier 34295, France; CHU Montpellier, ART/PGD Division, Hôpital Arnaud de Villeneuve, Montpellier, Cedex 5, Montpellier 34295, France.
| |
Collapse
|
41
|
Beurois J, Martinez G, Cazin C, Kherraf ZE, Amiri-Yekta A, Thierry-Mieg N, Bidart M, Petre G, Satre V, Brouillet S, Touré A, Arnoult C, Ray PF, Coutton C. CFAP70 mutations lead to male infertility due to severe astheno-teratozoospermia. A case report. Hum Reprod 2019; 34:2071-2079. [DOI: 10.1093/humrep/dez166] [Citation(s) in RCA: 28] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2019] [Revised: 07/14/2019] [Indexed: 11/13/2022] Open
Abstract
Abstract
The use of high-throughput sequencing techniques has allowed the identification of numerous mutations in genes responsible for severe astheno-teratozoospermia due to multiple morphological abnormalities of the sperm flagella (MMAF). However, more than half of the analysed cases remain unresolved suggesting that many yet uncharacterised gene defects account for this phenotype. Based on whole-exome sequencing data from a large cohort of 167 MMAF-affected subjects, we identified two unrelated affected individuals carrying a homozygous deleterious mutation in CFAP70, a gene not previously linked to the MMAF phenotype. One patient had a homozygous splice variant c.1723-1G>T, altering a consensus splice acceptor site of CFAP70 exon 16, and one had a likely deleterious missense variant in exon 3 (p.Phe60Ile). The CFAP70 gene encodes a regulator protein of the outer dynein arms (ODA) strongly expressed in the human testis. In the sperm cells from the patient carrying the splice variant, immunofluorescence (IF) experiments confirmed the absence of the protein in the sperm flagellum. Moreover, IF analysis showed the absence of markers for the ODAs and the central pair complex of the axoneme. Interestingly, whereas CFAP70 staining was present in sperm cells from patients with mutations in the three other MMAF-related genes ARMC2, FSIP2 and CFAP43, we observed an absence of staining in sperm cells from patients mutated in the WDR66 gene, suggesting a possible interaction between two different axonemal components. In conclusion, this work provides the first evidence that loss of CFAP70 function causes MMAF and that ODA-related proteins may be crucial for the assembly and/or stability of the flagellum axoneme in addition to its motility.
Collapse
Affiliation(s)
- Julie Beurois
- INSERM U1209, CNRS UMR 5309, Institute for Advanced Biosciences, Université Grenoble Alpes, 38000 Grenoble, France
| | - Guillaume Martinez
- INSERM U1209, CNRS UMR 5309, Institute for Advanced Biosciences, Université Grenoble Alpes, 38000 Grenoble, France
- CHU Grenoble Alpes, UM de Génétique Chromosomique, Grenoble, France
| | - Caroline Cazin
- INSERM U1209, CNRS UMR 5309, Institute for Advanced Biosciences, Université Grenoble Alpes, 38000 Grenoble, France
| | - Zine-Eddine Kherraf
- INSERM U1209, CNRS UMR 5309, Institute for Advanced Biosciences, Université Grenoble Alpes, 38000 Grenoble, France
- CHU de Grenoble, UM GI-DPI, Grenoble, F-38000, France
| | - Amir Amiri-Yekta
- Department of Genetics, Reproductive Biomedicine Research Center, Royan Institute for Reproductive Biomedicine, ACECR, Tehran, Iran
| | | | - Marie Bidart
- INSERM U1205, UFR Chimie Biologie, Université Grenoble Alpes, Grenoble, France
| | - Graciane Petre
- INSERM U1205, UFR Chimie Biologie, Université Grenoble Alpes, Grenoble, France
| | - Véronique Satre
- INSERM U1209, CNRS UMR 5309, Institute for Advanced Biosciences, Université Grenoble Alpes, 38000 Grenoble, France
- CHU Grenoble Alpes, UM de Génétique Chromosomique, Grenoble, France
| | - Sophie Brouillet
- Laboratoire d'AMP-CECOS, CHU Grenoble-Alpes, U1036 INSERM-UGA-CEA-CNRS, Université Grenoble Alpes, 38000 Grenoble, France
| | - Aminata Touré
- INSERM U1016, Institut Cochin, Paris 75014, France
- UMR 8104, Centre National de la Recherche Scientifique, Paris 75014, France
- Faculté de Médecine, Université Paris Descartes, Sorbonne Paris Cité, Paris 75014, France
| | - Christophe Arnoult
- INSERM U1209, CNRS UMR 5309, Institute for Advanced Biosciences, Université Grenoble Alpes, 38000 Grenoble, France
| | - Pierre F Ray
- INSERM U1209, CNRS UMR 5309, Institute for Advanced Biosciences, Université Grenoble Alpes, 38000 Grenoble, France
- CHU de Grenoble, UM GI-DPI, Grenoble, F-38000, France
| | - Charles Coutton
- INSERM U1209, CNRS UMR 5309, Institute for Advanced Biosciences, Université Grenoble Alpes, 38000 Grenoble, France
- CHU Grenoble Alpes, UM de Génétique Chromosomique, Grenoble, France
| |
Collapse
|
42
|
Fournier A, Andreeva A, Gala A, Brouillet S, Brunet C, Vincens C, Hamamah S. Usable blastocyst development rate is influenced by maternal age and ultra-low oxygen tension in extended culture. Fertil Steril 2019. [DOI: 10.1016/j.fertnstert.2019.07.498] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
43
|
Abi Nahed R, Reynaud D, Borg AJ, Traboulsi W, Wetzel A, Sapin V, Brouillet S, Dieudonné MN, Dakouane-Giudicelli M, Benharouga M, Murthi P, Alfaidy N. NLRP7 is increased in human idiopathic fetal growth restriction and plays a critical role in trophoblast differentiation. J Mol Med (Berl) 2019; 97:355-367. [PMID: 30617930 DOI: 10.1007/s00109-018-01737-x] [Citation(s) in RCA: 26] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2018] [Revised: 12/18/2018] [Accepted: 12/21/2018] [Indexed: 12/13/2022]
Abstract
Fetal growth restriction (FGR) the leading cause of perinatal mortality and morbidity is highly related to abnormal placental development, and placentas from FGR pregnancies are often characterized by increased inflammation. However, the mechanisms of FGR-associated inflammation are far from being understood. NLRP7, a member of a family of receptors involved in the innate immune responses, has been shown to be associated with gestational trophoblastic diseases. Here, we characterized the expression and the functional role of NLRP7 in the placenta and investigated its involvement in the pathogenesis of FGR. We used primary trophoblasts and placental explants that were collected during early pregnancy, and established trophoblast-derived cell lines, human placental villi, and serum samples from early pregnancy (n = 38) and from FGR (n = 40) and age-matched controls (n = 32). Our results show that NLRP7 (i) is predominantly expressed in the trophoblasts during the hypoxic period of placental development and its expression is upregulated by hypoxia and (ii) increases trophoblast proliferation ([3H]-thymidine) and controls the precocious differentiation of trophoblasts towards syncytium (syncytin 1 and 2 and β-hCG production and xCELLigence analysis) and towards invasive extravillous trophoblast (2D and 3D cultures). We have also demonstrated that NLRP7 inflammasome activation in trophoblast cells increases IL-1β, but not IL-18 secretion. In relation to the FGR, we demonstrated that major components of NLRP7 inflammasome machinery are increased and that IL-1β but not IL-18 circulating levels are increased in FGR. Altogether, our results identified NLRP7 as a critical placental factor and provided evidence for its deregulation in FGR. NLRP7 inflammasome is abundantly expressed by trophoblast cells. It is regulated by a key parameter of placental development, hypoxia. It controls trophoblast proliferation, migration, and invasion and exhibits anti-apoptotic role. NLRP7 machinery is deregulated in FGR pregnancies. KEY MESSAGES: NLRP7 inflammasome is abundantly expressed by trophoblast cells. It is regulated by a key parameter of placental development, hypoxia. It controls trophoblast proliferation, migration, and invasion and exhibits anti-apoptotic role. NLRP7 machinery is deregulated in FGR pregnancies.
Collapse
Affiliation(s)
- R Abi Nahed
- Institut National de la Santé et de la Recherche Médicale, Unité 1036, Grenoble, France.,Université Grenoble-Alpes, 38000, Grenoble, France.,Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA), Biosciences and Biotechnology Institute of Grenoble, Grenoble, France
| | - D Reynaud
- Institut National de la Santé et de la Recherche Médicale, Unité 1036, Grenoble, France.,Université Grenoble-Alpes, 38000, Grenoble, France.,Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA), Biosciences and Biotechnology Institute of Grenoble, Grenoble, France
| | - A J Borg
- Department of Medicine, School of Clinical Sciences, Monash University and the Ritchie Centre, Hudson Institute of Medical Research, Clayton, Victoria, Australia.,Department of Maternal-Fetal Medicine, Pregnancy Research Centre, The Royal Women's Hospital, Parkville, Victoria, Australia
| | - W Traboulsi
- Institut National de la Santé et de la Recherche Médicale, Unité 1036, Grenoble, France.,Université Grenoble-Alpes, 38000, Grenoble, France.,Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA), Biosciences and Biotechnology Institute of Grenoble, Grenoble, France
| | - A Wetzel
- Université Grenoble-Alpes, 38000, Grenoble, France.,Hôpital Couple-Enfant, Centre Clinique et Biologique d'Assistance Médicale à la Procréation-CECOS, Centre Hospitalier Universitaire de Grenoble, 38700, La Tronche, France
| | - V Sapin
- GReD, UMR CNRS 6293 INSERM 1103 Université Clermont Auvergne, CRBC, UFR de Médecine et des Professions Paramédicales, 63000, Clermont-Ferrand, France
| | - S Brouillet
- Institut National de la Santé et de la Recherche Médicale, Unité 1036, Grenoble, France.,Université Grenoble-Alpes, 38000, Grenoble, France.,Hôpital Couple-Enfant, Centre Clinique et Biologique d'Assistance Médicale à la Procréation-CECOS, Centre Hospitalier Universitaire de Grenoble, 38700, La Tronche, France
| | - M N Dieudonné
- GIG - EA 7404 Université de Versailles-Saint-Quentin-en-Yvelines, Université Paris-Saclay, Unité de Formation et de Recherche des Sciences de la Santé Simone Veil, Montigny-le-Bretonneux, France
| | - M Dakouane-Giudicelli
- Institut National de la Santé et de la Recherche Médicale, Unité 1179, Montigny-Le-Bretonneux, France
| | - M Benharouga
- Université Grenoble-Alpes, 38000, Grenoble, France.,Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA), Biosciences and Biotechnology Institute of Grenoble, Grenoble, France.,Unité Mixte de Recherche 5249, Laboratoire de Chimie et Biologie des Métaux, Centre National de la Recherche Scientifique, Grenoble, France
| | - P Murthi
- Department of Medicine, School of Clinical Sciences, Monash University and the Ritchie Centre, Hudson Institute of Medical Research, Clayton, Victoria, Australia.,Department of Maternal-Fetal Medicine, Pregnancy Research Centre, The Royal Women's Hospital, Parkville, Victoria, Australia.,Department of Obstetrics and Gynaecology, The University of Melbourne, Parkville, Victoria, Australia
| | - Nadia Alfaidy
- Institut National de la Santé et de la Recherche Médicale, Unité 1036, Grenoble, France. .,Université Grenoble-Alpes, 38000, Grenoble, France. .,Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA), Biosciences and Biotechnology Institute of Grenoble, Grenoble, France. .,Unité INSERM U1036, Laboratoire BCI -BIG, CEA Grenoble 17, rue des Martyrs, 38054, Grenoble cedex 9, France.
| |
Collapse
|
44
|
Anav M, Phillips S, Ferrieres Hoa A, Gala A, Fournier A, Maris E, Grysole C, Bissonnette F, Brouillet S, Kadoch I, Hamamah S. Embryo cryopreservation process is associated with significantly higher birth weight in a sibling embryo cohort: a multicentric study. Fertil Steril 2018. [DOI: 10.1016/j.fertnstert.2018.07.972] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
45
|
Lamotte A, Martinez G, Devillard F, Hograindleur JP, Satre V, Coutton C, Harbuz R, Amblard F, Lespinasse J, Benchaib M, Bessonnat J, Brouillet S, Hennebicq S. Is sperm FISH analysis still useful for Robertsonian translocations? Meiotic analysis for 23 patients and review of the literature. Basic Clin Androl 2018; 28:5. [PMID: 29760927 PMCID: PMC5937048 DOI: 10.1186/s12610-018-0069-z] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2017] [Accepted: 03/08/2018] [Indexed: 01/09/2023] Open
Abstract
Background Robertsonian translocations (RobT) are common structural chromosome rearrangements where carriers display a majority of chromosomally balanced spermatozoa from alternate segregation mode. According to some monotony observed in the rates of balanced segregation, is sperm FISH analysis obsolete for RobT carriers? Methods Retrospective cohort research study on 23 patients analyzed in our center from 2003 to 2017 and compared to the data of 187 patients in literature from 1983 to 2017. Robertsonian translocation carriers were divided in six groups according to the chromosomes involved in the translocation: 9 patients from our center and 107 from literature carrying 45,XY,der(13;14) karyotype, 3 and 35 patients respectively with 45,XY,der(14;21), 5 and 11 patients respectively with 45,XY,der(13;15), 4 and 7 patients respectively with 45,XY,der(14;15), 1 and 4 patients respectively with 45,XY,der(13;22),and 1 and 10 patients respectively with 45,XY,der(14;22). Results Alternate segregation mode is predominant in our group of Robertsonian translocation carriers with 73.45% ±8.05 of balanced spermatozoa (min 50.92%; max 89.99%). These results are compliant with the data from literature for all translocations types (p > 0.05) and are consistent among the different types of Robertsonian translocations (p > 0.05) except for der(13;15) that exhibit lower balanced spermatozoa rates (p < 0.05 versus der(13;14), der(14;21), (13;21) and der(15;22)). Normozoospermic patients also display a significantly (p < 0.01) higher rate of balanced sperm cells than patients with abnormal seminograms whatever the defect implied. Conclusions According to the discrepancies observed between der(13;15) and all the other Rob T carriers, the differences observed among patients presenting normal and abnormal sperm parameters and the input in genetical counselling, sperm FISH does not seem obsolete for these patients. Moreover, it seems important to collect more data for rare RobT.
Collapse
Affiliation(s)
- Anna Lamotte
- CHU de Grenoble, UF de Biologie de la procréation, F-38000 Grenoble, France.,3Université Grenoble Alpes, F-38000 Grenoble, France
| | - Guillaume Martinez
- CHU de Grenoble, UF de Génétique Chromosomique, F-38000 Grenoble, France.,3Université Grenoble Alpes, F-38000 Grenoble, France.,Team 'Genetics Epigenetics and Therapies of Infertility', Institute for Advanced Biosciences INSERM U1209, CNRS UMR5309, F-38000 Grenoble, France
| | | | - Jean-Pascal Hograindleur
- 3Université Grenoble Alpes, F-38000 Grenoble, France.,Team 'Genetics Epigenetics and Therapies of Infertility', Institute for Advanced Biosciences INSERM U1209, CNRS UMR5309, F-38000 Grenoble, France
| | - Véronique Satre
- CHU de Grenoble, UF de Génétique Chromosomique, F-38000 Grenoble, France.,3Université Grenoble Alpes, F-38000 Grenoble, France.,Team 'Genetics Epigenetics and Therapies of Infertility', Institute for Advanced Biosciences INSERM U1209, CNRS UMR5309, F-38000 Grenoble, France
| | - Charles Coutton
- CHU de Grenoble, UF de Génétique Chromosomique, F-38000 Grenoble, France.,3Université Grenoble Alpes, F-38000 Grenoble, France.,Team 'Genetics Epigenetics and Therapies of Infertility', Institute for Advanced Biosciences INSERM U1209, CNRS UMR5309, F-38000 Grenoble, France
| | - Radu Harbuz
- CHU de Grenoble, UF de Génétique Chromosomique, F-38000 Grenoble, France
| | - Florence Amblard
- CHU de Grenoble, UF de Génétique Chromosomique, F-38000 Grenoble, France
| | | | | | - Julien Bessonnat
- CHU de Grenoble, UF de Biologie de la procréation, F-38000 Grenoble, France
| | - Sophie Brouillet
- CHU de Grenoble, UF de Biologie de la procréation, F-38000 Grenoble, France.,3Université Grenoble Alpes, F-38000 Grenoble, France
| | - Sylviane Hennebicq
- CHU de Grenoble, UF de Biologie de la procréation, F-38000 Grenoble, France.,3Université Grenoble Alpes, F-38000 Grenoble, France.,Team 'Genetics Epigenetics and Therapies of Infertility', Institute for Advanced Biosciences INSERM U1209, CNRS UMR5309, F-38000 Grenoble, France
| |
Collapse
|
46
|
Dong FN, Amiri-Yekta A, Martinez G, Saut A, Tek J, Stouvenel L, Lorès P, Karaouzène T, Thierry-Mieg N, Satre V, Brouillet S, Daneshipour A, Hosseini SH, Bonhivers M, Gourabi H, Dulioust E, Arnoult C, Touré A, Ray PF, Zhao H, Coutton C. Absence of CFAP69 Causes Male Infertility due to Multiple Morphological Abnormalities of the Flagella in Human and Mouse. Am J Hum Genet 2018; 102:636-648. [PMID: 29606301 DOI: 10.1016/j.ajhg.2018.03.007] [Citation(s) in RCA: 103] [Impact Index Per Article: 17.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2017] [Accepted: 03/05/2018] [Indexed: 10/17/2022] Open
Abstract
The multiple morphological abnormalities of the flagella (MMAF) phenotype is among the most severe forms of sperm defects responsible for male infertility. The phenotype is characterized by the presence in the ejaculate of immotile spermatozoa with severe flagellar abnormalities including flagella being short, coiled, absent, and of irregular caliber. Recent studies have demonstrated that MMAF is genetically heterogeneous, and genes thus far associated with MMAF account for only one-third of cases. Here we report the identification of homozygous truncating mutations (one stop-gain and one splicing variant) in CFAP69 of two unrelated individuals by whole-exome sequencing of a cohort of 78 infertile men with MMAF. CFAP69 encodes an evolutionarily conserved protein found at high levels in the testis. Immunostaining experiments in sperm from fertile control individuals showed that CFAP69 localized to the midpiece of the flagellum, and the absence of CFAP69 was confirmed in both individuals carrying CFPA69 mutations. Additionally, we found that sperm from a Cfap69 knockout mouse model recapitulated the MMAF phenotype. Ultrastructural analysis of testicular sperm from the knockout mice showed severe disruption of flagellum structure, but histological analysis of testes from these mice revealed the presence of all stages of the seminiferous epithelium, indicating that the overall progression of spermatogenesis is preserved and that the sperm defects likely arise during spermiogenesis. Together, our data indicate that CFAP69 is necessary for flagellum assembly/stability and that in both humans and mice, biallelic truncating mutations in CFAP69 cause autosomal-recessive MMAF and primary male infertility.
Collapse
|
47
|
Reynaud D, Sergent F, Abi Nahed R, Brouillet S, Benharouga M, Alfaidy N. Erratum to: EG-VEGF Maintenance Over Early Gestation to Develop a Pregnancy-Induced Hypertensive Animal Model. Methods Mol Biol 2018; 1710:E1. [PMID: 29704221 DOI: 10.1007/978-1-4939-7498-6_29] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/08/2023]
Affiliation(s)
- Déborah Reynaud
- Unité U1036, Institut National de la Santé et de la Recherche Médicale, Grenoble, France
- University Grenoble-Alpes, 38000, Grenoble, France
- Commissariat à l'Energie Atomique (CEA), BIG - Biology of Cancer and Infection, Grenoble, France
| | - Frédéric Sergent
- Unité U1036, Institut National de la Santé et de la Recherche Médicale, Grenoble, France
- University Grenoble-Alpes, 38000, Grenoble, France
- Commissariat à l'Energie Atomique (CEA), BIG - Biology of Cancer and Infection, Grenoble, France
| | - Roland Abi Nahed
- Unité U1036, Institut National de la Santé et de la Recherche Médicale, Grenoble, France
- University Grenoble-Alpes, 38000, Grenoble, France
- Commissariat à l'Energie Atomique (CEA), BIG - Biology of Cancer and Infection, Grenoble, France
| | - Sophie Brouillet
- Unité U1036, Institut National de la Santé et de la Recherche Médicale, Grenoble, France
- University Grenoble-Alpes, 38000, Grenoble, France
- Commissariat à l'Energie Atomique (CEA), BIG - Biology of Cancer and Infection, Grenoble, France
- Department of Obstetrics and Gyneacology, et Laboratoire d'Aide à la Procréation-CECOS La Tronche, University Hospital of Grenoble, Grenoble, France
| | - Mohamed Benharouga
- University Grenoble-Alpes, 38000, Grenoble, France
- Commissariat à l'Energie Atomique (CEA), BIG - Biology of Cancer and Infection, Grenoble, France
- Centre National de la Recherche Scientifique, Unité Mixte de Recherche 5249, Laboratoire de Chimie et Biologie des Métaux, Grenoble, France
| | - Nadia Alfaidy
- Unité U1036, Institut National de la Santé et de la Recherche Médicale, Grenoble, France.
- University Grenoble-Alpes, 38000, Grenoble, France.
- Commissariat à l'Energie Atomique (CEA), BIG - Biology of Cancer and Infection, Grenoble, France.
- Unité INSERM U1036, Laboratoire BCI -BIG, CEA Grenoble 17, rue des Martyrs, 38054, Grenoble Cedex 9, France.
| |
Collapse
|
48
|
Traboulsi W, Sergent F, Boufettal H, Brouillet S, Slim R, Hoffmann P, Benlahfid M, Zhou QY, Balboni G, Onnis V, Bolze PA, Salomon A, Sauthier P, Mallet F, Aboussaouira T, Feige JJ, Benharouga M, Alfaidy N. Antagonism of EG-VEGF Receptors as Targeted Therapy for Choriocarcinoma Progression In Vitro and In Vivo. Clin Cancer Res 2017; 23:7130-7140. [PMID: 28899975 DOI: 10.1158/1078-0432.ccr-17-0811] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2017] [Revised: 06/26/2017] [Accepted: 08/31/2017] [Indexed: 11/16/2022]
Abstract
Purpose: Choriocarcinoma (CC) is the most malignant gestational trophoblastic disease that often develops from complete hydatidiform moles (CHM). Neither the mechanism of CC development nor its progression is yet characterized. We recently identified endocrine gland-derived vascular endothelial growth factor (EG-VEGF) as a novel key placental growth factor that controls trophoblast proliferation and invasion. EG-VEGF acts via two receptors, PROKR1 and PROKR2. Here, we demonstrate that EG-VEGF receptors can be targeted for CC therapy.Experimental Design: Three approaches were used: (i) a clinical investigation comparing circulating EG-VEGF in control (n = 20) and in distinctive CHM (n = 38) and CC (n = 9) cohorts, (ii) an in vitro study investigating EG-VEGF effects on the CC cell line JEG3, and (iii) an in vivo study including the development of a novel CC mouse model, through a direct injection of JEG3-luciferase into the placenta of gravid SCID-mice.Results: Both placental and circulating EG-VEGF levels were increased in CHM and CC (×5) patients. EG-VEGF increased JEG3 proliferation, migration, and invasion in two-dimensional (2D) and three-dimensional (3D) culture systems. JEG3 injection in the placenta caused CC development with large metastases compared with their injection into the uterine horn. Treatment of the animal model with EG-VEGF receptor's antagonists significantly reduced tumor development and progression and preserved pregnancy. Antibody-array and immunohistological analyses further deciphered the mechanism of the antagonist's actions.Conclusions: Our work describes a novel preclinical animal model of CC and presents evidence that EG-VEGF receptors can be targeted for CC therapy. This may provide safe and less toxic therapeutic options compared with the currently used multi-agent chemotherapies. Clin Cancer Res; 23(22); 7130-40. ©2017 AACR.
Collapse
Affiliation(s)
- Wael Traboulsi
- Institut National de la Santé et de la Recherche Médicale, Unité Grenoble, Grenoble, France.,University Grenoble-Alpes, Grenoble, France.,Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA), Biosciences and Biotechnology Institute of Grenoble, Grenoble, France
| | - Frédéric Sergent
- Institut National de la Santé et de la Recherche Médicale, Unité Grenoble, Grenoble, France.,University Grenoble-Alpes, Grenoble, France.,Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA), Biosciences and Biotechnology Institute of Grenoble, Grenoble, France
| | - Houssine Boufettal
- Faculty of Medicine and Pharmacy, University Hassan II Casablanca and Ibn Rochd Hospital of Casablanca, Obstetrics and Gynecology Department, Casablanca, Morocco
| | - Sophie Brouillet
- Institut National de la Santé et de la Recherche Médicale, Unité Grenoble, Grenoble, France.,University Grenoble-Alpes, Grenoble, France.,Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA), Biosciences and Biotechnology Institute of Grenoble, Grenoble, France.,University Hospital of Grenoble, Department of Obstetrics and Gynaecology, and Laboratoire d'Aide à la Procréation-CECOS, La Tronche, France
| | - Rima Slim
- Department of Human Genetics, McGill University Health Centre Research Institute, Montréal, Quebec, Canada
| | - Pascale Hoffmann
- Institut National de la Santé et de la Recherche Médicale, Unité Grenoble, Grenoble, France.,University Grenoble-Alpes, Grenoble, France.,Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA), Biosciences and Biotechnology Institute of Grenoble, Grenoble, France.,University Hospital of Grenoble, Department of Obstetrics and Gynaecology, and Laboratoire d'Aide à la Procréation-CECOS, La Tronche, France
| | - Mohammed Benlahfid
- Faculty of Medicine and Pharmacy, University Hassan II Casablanca and Ibn Rochd Hospital of Casablanca, Obstetrics and Gynecology Department, Casablanca, Morocco
| | - Qun Y Zhou
- Department of Pharmacology, University of California, Irvine, California
| | - Gianfranco Balboni
- Department of Life and Environmental Sciences, University of Cagliari, Cagliari, Italy
| | - Valentina Onnis
- Department of Life and Environmental Sciences, University of Cagliari, Cagliari, Italy
| | - Pierre A Bolze
- University of Lyon 1, University Hospital Lyon Sud, Department of Gynecological Surgery and Oncology, Obstetrics, Lyon, France.,French Reference Center for Gestational Trophoblastic Diseases, University Hospital Lyon Sud, Chemin du Grand Revoyet, Pierre Bénite, Lyon, France.,Joint Unit Hospices Civils de Lyon-bioMerieux, Cancer Biomarkers Research Group, University Hospital Lyon Sud, Lyon, France
| | - Aude Salomon
- Institut National de la Santé et de la Recherche Médicale, Unité Grenoble, Grenoble, France.,University Grenoble-Alpes, Grenoble, France.,Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA), Biosciences and Biotechnology Institute of Grenoble, Grenoble, France
| | - Philippe Sauthier
- Department of Human Genetics, McGill University Health Centre Research Institute, Montréal, Quebec, Canada
| | - François Mallet
- Joint Unit Hospices Civils de Lyon-bioMerieux, Cancer Biomarkers Research Group, University Hospital Lyon Sud, Lyon, France.,EA 7426 Pathophysiology of Injury-induced Immunosuppression, University of Lyon 1 Hospices Civils de Lyon bioMérieux, Hôpital Edouard Herriot, Lyon, France
| | - Touria Aboussaouira
- Faculty of Medicine and Pharmacy, University Hassan II Casablanca and Ibn Rochd Hospital of Casablanca, Obstetrics and Gynecology Department, Casablanca, Morocco
| | - Jean J Feige
- Institut National de la Santé et de la Recherche Médicale, Unité Grenoble, Grenoble, France.,University Grenoble-Alpes, Grenoble, France.,Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA), Biosciences and Biotechnology Institute of Grenoble, Grenoble, France
| | - Mohamed Benharouga
- University Grenoble-Alpes, Grenoble, France.,Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA), Biosciences and Biotechnology Institute of Grenoble, Grenoble, France.,Centre National de la Recherche Scientifique, Unité Mixte de Recherche, Laboratoire de Chimie et Biologie des Métaux, Grenoble, France
| | - Nadia Alfaidy
- Institut National de la Santé et de la Recherche Médicale, Unité Grenoble, Grenoble, France. .,University Grenoble-Alpes, Grenoble, France.,Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA), Biosciences and Biotechnology Institute of Grenoble, Grenoble, France
| |
Collapse
|
49
|
Traboulsi W, Sergent F, Brouillet S, Boufettal H, Hoffmann P, Zhou QY, Balboni G, Aboussaouira T, Feige JJ, Benharouga M, Alfaidy N. Antagonism of EG-VEGF receptors is a novel targeted therapy for choriocarcinoma progression: in vitro, in vivo and in clinical studies. Placenta 2017. [DOI: 10.1016/j.placenta.2017.07.040] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
50
|
Gonçalves IR, Brouillet S, Soulié MC, Gribaldo S, Sirven C, Charron N, Boccara M, Choquer M. Genome-wide analyses of chitin synthases identify horizontal gene transfers towards bacteria and allow a robust and unifying classification into fungi. BMC Evol Biol 2016; 16:252. [PMID: 27881071 PMCID: PMC5122149 DOI: 10.1186/s12862-016-0815-9] [Citation(s) in RCA: 32] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2016] [Accepted: 10/28/2016] [Indexed: 12/11/2022] Open
Abstract
BACKGROUND Chitin, the second most abundant biopolymer on earth after cellulose, is found in probably all fungi, many animals (mainly invertebrates), several protists and a few algae, playing an essential role in the development of many of them. This polysaccharide is produced by type 2 glycosyltransferases, called chitin synthases (CHS). There are several contradictory classifications of CHS isoenzymes and, as regards their evolutionary history, their origin and diversity is still a matter of debate. RESULTS A genome-wide analysis resulted in the detection of more than eight hundred putative chitin synthases in proteomes associated with about 130 genomes. Phylogenetic analyses were performed with special care to avoid any pitfalls associated with the peculiarities of these sequences (e.g. highly variable regions, truncated or recombined sequences, long-branch attraction). This allowed us to revise and unify the fungal CHS classification and to study the evolutionary history of the CHS multigenic family. This update has the advantage of being user-friendly due to the development of a dedicated website ( http://wwwabi.snv.jussieu.fr/public/CHSdb ), and it includes any correspondences with previously published classifications and mutants. Concerning the evolutionary history of CHS, this family has mainly evolved via duplications and losses. However, it is likely that several horizontal gene transfers (HGT) also occurred in eukaryotic microorganisms and, even more surprisingly, in bacteria. CONCLUSIONS This comprehensive multi-species analysis contributes to the classification of fungal CHS, in particular by optimizing its robustness, consensuality and accessibility. It also highlights the importance of HGT in the evolutionary history of CHS and describes bacterial chs genes for the first time. Many of the bacteria that have acquired a chitin synthase are plant pathogens (e.g. Dickeya spp; Pectobacterium spp; Brenneria spp; Agrobacterium vitis and Pseudomonas cichorii). Whether they are able to produce a chitin exopolysaccharide or secrete chitooligosaccharides requires further investigation.
Collapse
Affiliation(s)
- Isabelle R Gonçalves
- Univ Lyon, Université Claude Bernard Lyon 1, CNRS UMR5240, Microbiologie Adaptation et Pathogénie, Bâtiment André Lwoff, 10 rue Raphaël Dubois, F-69622, Villeurbanne, France. .,BAYER S.A.S., Centre de Recherche de la Dargoire, F-69263, Lyon, France.
| | - Sophie Brouillet
- Sorbonne Universités, UPMC Univ Paris 06, UMR 7205 (MNHN, UPMC, CNRS, EPHE), Atelier de Bioinformatique, F-75231, Paris, Cedex 05, France
| | - Marie-Christine Soulié
- Sorbonne Universités, UPMC Univ Paris 06, INRA-AgroParisTech UMR1318, F-78026, Versailles, France
| | - Simonetta Gribaldo
- Institut Pasteur, Unité Biologie Moléculaire du Gène chez les Extrêmophiles, Département de Microbiologie, 25 rue du Docteur Roux, F-75015, Paris, France
| | - Catherine Sirven
- BAYER S.A.S., Centre de Recherche de la Dargoire, F-69263, Lyon, France
| | - Noémie Charron
- BAYER S.A.S., Centre de Recherche de la Dargoire, F-69263, Lyon, France
| | - Martine Boccara
- Sorbonne Universités, UPMC Univ Paris 06, UMR 7205 (MNHN, UPMC, CNRS, EPHE), Atelier de Bioinformatique, F-75231, Paris, Cedex 05, France
| | - Mathias Choquer
- Univ Lyon, Université Claude Bernard Lyon 1, CNRS UMR5240, Microbiologie Adaptation et Pathogénie, Bâtiment André Lwoff, 10 rue Raphaël Dubois, F-69622, Villeurbanne, France.,BAYER S.A.S., Centre de Recherche de la Dargoire, F-69263, Lyon, France
| |
Collapse
|